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Abstract 
The optimal approach for the ablation of persistent atrial fibrillation is undefined. Left atrial 
posterior wall isolation (LAPWI) is a promising lesion set, based on techniques for surgical AF 
ablation. The left atrial posterior wall can be isolated via catheter, surgical or hybrid ablation 
techniques. This MD thesis aims to inform a comparative trial of catheter versus hybrid 
ablation.  
 
In series of catheter and hybrid ablation with left atrial posterior wall isolation in patients 
with atrial fibrillation outcomes are suggested to be superior to published outcomes of 
alternative lesion sets. A complete lesion set with intact LAPWI ablation lines is important 
for outcomes and one advantage of a two-stage hybrid ablation may be that is provides 
greater chance of electrical isolation. It also gives rises to significant reductions in surface 
ECG P wave duration and dispersion which are associated with better ablation outcomes, 
possibly due to autonomic modulation. The benefits of hybrid ablation come at a cost of 
complications, however. Newer catheter ablation technologies such as electroporation may 
reduce risks and experiments on porcine models described in this thesis demonstrate how 
this is possible and provide a future avenue for research and development.    
 
A technique is also described for checking the LAPWI lesion set via the use of an 
oesophageal pacing electrode. Feasibility is demonstrated when compared to simultaneous 
intracardiac study and a standalone “outpatient” technique is developed. This technique 
could be used for research or as part of standard follow-up of LAPWI via catheter or surgery.  
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Left Atrial Posterior Wall Ablation in the 
Treatment of Atrial Fibrillation 
1 Chapter 1 - Introduction 
1.1  Introduction 
Atrial Fibrillation is the most common supraventricular arrhythmia, characterised by disorganised 
chaotic contraction of the atria. Although not life-threatening, the condition has a significant impact 
on quality of life and the thromboembolic risk is associated with substantial mortality and morbidity. 
In the Framingham Heart study the presence of AF was associated with a 50-90% increase in 
mortality1. As the general population ages the prevalence of AF is increasing and with this the 
burden and cost on health services are rising.  
1.1.1 History of Atrial Fibrillation 
 
The characteristic irregular pulse of Atrial fibrillation (AF) is described in contemporary reports by 
physicians from ancient China, India and Greece including Hippocrates and the Chinese Emperor 
Huang Ti Nei Ching Su Wen.  The famous anatomist William Harvey was probably the first to 
describe “fibrillation of the auricles” in animals in 1628 but the development of the 
electrocardiograph by William Eindhoven in 1900 started the 20th century field of cardiac 
electrophysiology and enabled Sir Thomas Lewis to record an ECG from a patient in Atrial Fibrillation.  
Many of the theories of atrial fibrillation developed in the early 20th century are still relevant today 
and despite many competing theories of atrial fibrillation development generated from animal 
research a universal theory of AF development remains elusive.  In the late 20th century the 
development of invasive electrophysiology has led to increased human study of AF with definitive 
treatments such as catheter ablation that aim to cure the condition.  
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1.1.2 Atrial fibrillation definitions 
 
Atrial fibrillation is defined by the European Society of Cardiology as 
“A cardiac arrhythmia with the following characteristics:  
(1) The surface ECG shows ‘absolutely’ irregular RR intervals (AF is therefore sometimes known as 
arrhythmia absoluta), i.e. RR intervals that do not follow a repetitive pattern.  
(2) There are no distinct P waves on the surface ECG. Some apparently regular atrial electrical 
activity may be seen in some ECG leads, most often in lead V1.  
(3) The atrial cycle length (when visible), i.e. the interval between two atrial activations, is usually 
variable and <200 ms (>300 bpm).” 
International consensus is that there are five types of atrial fibrillation: 
1) First diagnosed episode of atrial fibrillation. This applies to all patients with AF regardless of 
duration of arrhythmia or severity of symptoms 
2) Paroxysmal atrial fibrillation is self-terminating and lasts less than seven days.  
3) Persistent atrial fibrillation is when atrial fibrillation lasts longer than seven days or 
termination with drugs or direct current cardioversion 
4) Longstanding persistent atrial fibrillation is when the arrhythmia has lasted longer than one 
year 
5) Permanent atrial fibrillation is when the arrhythmia has been accepted by the patient and 
physician and rate control is the definitive management plan.  
1.1.3 Epidemiology of Atrial fibrillation 
 
The prevalence of atrial fibrillation increases with age and the impact of atrial fibrillation on an aging 
UK population has significant socio-economic consequences for the National Health Service. It is one 
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of the most important public health problems faced by western countries and advances in treatment 
of cardiac and non-cardiac conditions mean the prevalence and resulting costs will rise. 
1.1.1 1.1.4 Prevalence of Atrial Fibrillation 
 
The 2001 ATRIA epidemiological study2 in 1.89 million Californian adults suggested an overall 
prevalence of Atrial Fibrillation of 0.95%. Prevalence increased with age from <0.1% in those under 
55 years to 9% in those over 80. The authors projected figures suggested the aging population would 
result in a 2.5 fold increase in the number of patients diagnosed with atrial fibrillation. A 2007 cross-
sectional study from Scotland gave similar results regarding atrial fibrillation prevalence3 however a 
more recent study from Sweden4 has suggested that prevalence of atrial fibrillation may be closer to 
3% and the accepted prevalence in international guidelines is a significant underestimate. This 
underestimate is likely to be due to the difficulty in the diagnosing atrial fibrillation in asymptomatic 
patients who may represent 10-15% of the AF population5.  
1.2  Causal factors associated with Atrial Fibrillation development 
 
A number of conditions are associated with the development of atrial fibrillation and in recent years 
the adjunctive treatment of these risk factors is increasingly recognised as an essential part of the 
management. This has lead to the integrated approach to atrial fibrillation with multi-disciplinary 
teams used to advise on lifestyle modifications and non-cardiac health interventions6. A recent 
meta-analysis of this approach has shown the promise of these clinics, which, despite their success, 
remain rare7. Condition’s that predispose to atrial fibrillation development are described below.  
1.2.1 Age 
 
Atrial fibrillation has a strong association with age as seen by the prevalence in the general 
population. The odds of developing atrial fibrillation increase significantly as people age with the 
lifetime risk from age forty onwards being 26%8. After the age of sixty the prevalence of AF doubles 
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with each decade and affects almost 10% of patients over the age of eighty. In the over 65 year old 
population AF is rarely a “lone” condition and usually co-exists with structural or cardiovascular 
heart disease9,10. The increasing elderly population in the western world, resulting from advances in 
medical science and the aging of the baby boomer generation, has led to forecasts of an epidemic of 
atrial fibrillation in the next 10-20 years11,12. While this is not solely down to the effects of age, age 
allows an accumulation of co-morbidities that increase the likelihood of AF development. The 




Male sex was associated with a 1.5 times greater risk than women of developing AF in the 
Framingham study10. The risk of stroke is greater in women13 however and this is recognised in the 
stoke assessment tool the CHADS2VaSc score where a point is scored for female sex.  
1.2.3 Race 
 
Initial population studies looking at the prevalence of atrial fibrillation were limited by a lack of racial 
diversity and unable to answer whether variations in AF prevalence existed. More recent studies 
have attempted to address this important question and highlighted significant racial differences14,15. 
Numerous studies have now demonstrated that AF is less prevalent in individuals of African descent 
compared to those with European ancestry. One study showed that with every 10% increase in 
European ancestry there was a 16-20% increased risk of AF16. 
  
A similar reduction in AF prevalence has been seen in Hispanics and Asians compared to white 
individuals. In the Multi-Ethnic Study of atherosclerosis, the age and sex adjusted incidence rates per 
1000 person years were 11.2 in white populations, 6.1 in Hispanics, 5.8 in African Americans and 3.9 
in Asians17. 
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It will be important to take into account the racial variation in AF risk in future UK healthcare 
planning. An appreciation of this difference is needed due to local variations in ethnicity and the 
inevitable changes that are seen nationally with immigration.  
1.2.4 Genetics 
 
It has long been known that AF can recur in families and in the Framingham study a parent with AF 
was a risk factor for AF development18. Subsequent analysis demonstrated a 40% increased risk of AF 
development if a first-degree relative was affected19. The first genes identified as being associated 
with AF were a gain of function mutation in the KVNQ1 gene, which encodes for the Iks potassium 
channel and the SCN5A gene, which encodes for a sodium channel. The picture has since been 
shown to be far more complex and the reduction in cost and increasing ease of synthesizing the 
human genome has resulted in numerous genome-wide association studies. These have 
demonstrated that AF is a complex polygenetic condition with genes involved in various roles 
including transcription factors, ion channels, myocytes and cytoskeletal proteins involved. These 
associations open up the possibility of further study into the mechanisms of AF along with novel and 
targeted therapies in certain populations20.  
1.2.5  Hypertension 
 
In the Framingham study hypertension was an independent risk factor for atrial fibrillation, 
increasing the risk of AF by 50% in men and 40% in women10. A population-based case control study 
of treated hypertensive patients showed a J shaped relationship between average systolic blood 
pressure and incidence of AF. Interestingly those with a systolic blood pressure of less than 120 
mmHg had an increased risk but excluding these led to a roughly linear increase in AF incidence with 
blood pressure21. Analysis of AF incidence in the women’s health study also showed increasing 
incidence of AF with increasing systolic and diastolic blood pressure. Systolic blood pressure was a 
slightly better risk marker and in this study for every increase of 10 mmHg of systolic blood pressure 
the incidence of atrial fibrillation the hazard ration for AF was 1.17 (95% CI, 1.08- 1.27; p < 0.0001)22.  
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The mechanism involved in increasing AF risk with hypertension is unclear, but several factors have 
been proposed. These include left ventricular hypertrophy, diastolic dysfunction and the effect of 
renin and angiotensin. These factors have been shown to lead to left atrial stretch, increased wall 
stress and fibrosis, which are all associated with the development of AF. 
1.2.6  Valvular Heart Disease 
 
It is well established that valvular heart disease is associated with the development of atrial 
fibrillation and increased the risk of AF in the Framingham cohort significantly (Odds ratio 1.8 in men 
and 3.4 in women)23.  Any structural valvular abnormality is thought to increase the risk of AF 
development but left sided lesions confer the highest risk, especially rheumatic mitral valve disease 
where up to 29% of those with isolated mitral stenosis are affected compared to 16% with isolated 
mitral regurgitation, 52% with mixed mitral valve disease and 1% of those with aortic valve disease24.  
 
1.2.7 Heart Failure 
 
Heart Failure and atrial fibrillation co-exist in up to 42% of patients and share risk factors. Each 
condition also increases the likelihood of the development of the other25. Women with AF have up 
to an 11-fold increased risk of developing heart failure while the risk is increased 3 fold for men10. AF 
is associated with adverse prognosis in heart failure and a two-fold increase in death1.   
 
AF Ablation has been associated with positive outcomes in heart failure patients such as exercise 
capacity26 and improvement in left ventricular ejection fraction27. The CASTLE-AF study, published in 
2018, was a large multicentre trial of heart failure patients with ICD’s and either paroxysmal or 
persistent AF. In the study AF ablation was associated with significantly fewer events of a composite 
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end-point of death and hospitalisation benefit as well as a significant reduction in death from any 
cause. The beneficial effect was seen predominately in patients in whom the left ventricular ejection 
fraction was between 25-35%. No benefit was seen in the most severe cases with an LVEF of <25%28.  
1.2.8  Obesity 
 
Obesity is a significant risk factor for atrial fibrillation and it has been increasingly recognised over 
recent years as a modifiable condition that can influence outcomes in atrial fibrillation. It is also 
associated with sleep apnoea, hypertension and diabetes mellitus, all of which are associated with 
an increase in AF. A meta-analysis of population based cohort studies by Wanahiti et al 
demonstrated a 49% increased risk of AF in the obese population and the risk of AF increased in 
parallel with body mass index29. Obesity is a global epidemic30 and the influence of this is likely to 
feed into the AF epidemic. 
 
A ground breaking series of studies in Adelaide, Australia by Prash Sanders’ group demonstrated that 
obesity caused structural and electrical changes, cardiac fibrosis and atrial fibrillation in sheep31 
which was reversed with weight loss32. This led to dedicated weight loss clinics, which ran alongside 
their electrophysiology service. Weight loss improved outcomes from AF ablation33 and the loss of 
ten per cent of body weight was associated with a six-fold increase in sinus rhythm and arrhythmia-
free survival34.  
 
The mechanism of obesity on the heart and the development of AF is complex. Several studies have 
shown an increase in pericardial fat is associated with AF development35,36 but the 
electrophysiological changes, reduced endocardial voltages and fibro-fatty infiltration in the left 
atrium37 and specifically the left atrial posterior wall are key factors31. The predominance of fatty 
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infiltration in the left atrial posterior wall highlights the role of this area of the heart in the 
development and perpetuation of persistent atrial fibrillation.  
1.2.9  Obstructive Sleep Apnoea 
 
Obstructive sleep apnoea (OSA) is a condition characterised by periods of breathing cessation during 
sleep and can be treated with continuous positive airway pressure ventilation (CPAP). It often co-
exists with atrial fibrillation and confers a four-fold increase in the development of AF38. Untreated 
OSA is associated with increased recurrence of AF following AF ablation where as appropriate 
treatment with the use of CPAP improves outcomes and reduces AF episodes39,40.  
1.2.10 Alcohol 
 
The ‘holiday heart syndrome’ where AF is triggered by a binge of alcohol is a well-known 
phenomenon41. Heavy habitual alcohol consumption confers an increased risk of developing AF and 
for every extra alcoholic drink per day the risk of AF increases by 8%42. Those with the highest intake 
of greater than three drinks per day have the highest risk (relative risk of 1.34 (CI 1.01 – 1.78))43. The 
impact of low levels of drinking have not been shown to be associated with an increased risk of AF 
but the difficulty in proving any relationship between AF and low levels of alcohol consumption in 
those without a previous diagnosis has been highlighted44.  
 
Mechanisms proposed to trigger AF by alcohol include autonomic changes such as a hyperadrenergic 
state and reduced vagal tone45–47.  Electrophysiological changes have also been shown to occur with 
alcohol including prolongation of atrial conduction time48 and shortening of refractory periods49 
following the consumption of alcohol. This combination shortens wavelengths and facilitates re-
entry and could allow for the triggering of AF. 
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1.2.11 Endocrine disease  
 
Diabetes Mellitus is associated with a 1.4-1.6 fold increased risk of atrial fibrillation in population 
studies10,50. There is significant overlap between co-morbidities such as obesity, hypertension and 
heart failure with diabetes mellitus. A recent meta-analysis of cohort studies has suggested an 
increased risk of AF of between 20-28% for those with diabetes. There was a dose-response 
relationship between increasing blood glucose and AF. It was not able to take into account the effect 
of obesity and adiposity and these are likely to be significant confounding factors51. 
 
Thyroid dysfunction is known to increase the risk of atrial fibrillation. Both hypothyroidism and 
hyperthyroidism have been shown to increase the vulnerability of atrial myocardium to AF in animal 
models, suggesting a role for stable thyroid function in the maintenance of sinus rhythm52. 
Hyperthyroidism is a common secondary cause of AF and risk has been shown to increase with 
decreasing levels of thyroid stimulating hormone as patients become more hyperthyroid. In the 
same population studies there was a low risk of AF in patients who were hypothyroid53,54. In 
euthyroid patients TSH levels were not associated with AF, instead increasing free T4 levels increase 
risk55,56. 
 
A proposed mechanism for hyperthyroidism increasing AF risk is increased B-adrenergic tone and 
increased automaticity of cardiac myocytes. This leads to increased firing of myocytes that act as AF 
triggers such as those in the pulmonary veins or elsewhere in the atria57. 
1.2.12  Exercise 
 
Regular exercise is beneficial for cardiometabolic health and mortality58,59. Regular light to moderate 
exercise improves cardiovascular health and therefore reduces the risk of AF60. In a cohort study of 
over 12000 patients who had undertaken treadmill testing at the Mayo clinic, and followed up for a 
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median of 14 years, physical fitness was associated with reduced risk of AF, stroke and mortality. For 
those patients with AF cardiorespiratory fitness was inversely related with stoke and mortality61.   
 
These beneficial effects of exercise are slightly off set by the increased risk of atrial arrhythmias in 
endurance athletes62–64. The increased risk may be as much as 8 fold by middle age for men who 
undertake regular intensive endurance65. There is a lack of data regarding the effects of endurance 
exercise in women and the possibility of gender specific differences in risk mean further study is 
clearly needed66,67. Similar atrial structural remodelling is seen in response to exercise in both 
genders but women have smaller right atria and increased myocardial deformation compared to 
men who are similarly conditioned68. 
 
A number of mechanisms are proposed to explain the increased risk of AF in endurance athletes. 
Exercise increases left atrial pressure, atrial volumes and P wave duration68,69. Further proarrhythmic 
changes in the atrial substrate are seen with exercise including myocardial fibrosis and myocardial 
inflammation, increasing atrial premature beats and increased vagal tone leading to bradycardia and 
decreased atrial refractoriness70,71,72.  
1.3  Clinical sequelae and Prognosis 
 
Atrial Fibrillation is associated was associated with increased mortality in the Framingham heart 
study with between a 1.5 and 1.9 fold increase in mortality when adjusted for pre-existing 
cardiovascular conditions. At 10-year follow-up 61.5% of men with AF between the ages of 55 and 
74 years of age had died compared with 30% of those without AF. In women it was 57.6% for those 
with AF versus 20.9% without. For patients without concurrent cardiovascular disease AF was 
associated with a two-fold risk of death1. 
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A meta-analysis of 104 studies involving over 9 million patients by Odutayo et al showed that AF was 
associated with an increased risk of all-cause mortality (Relative risk 1.46), cardiovascular mortality 
(2.03), major cardiovascular events (2.03), stroke (2.42), ischaemic stroke (2.33), ischaemic heart 
disease (1.61), sudden cardiac death (1.88), heart failure (4.99), chronic kidney disease (1.64) and 
peripheral arterial disease (1.31)73. 
 
Given increased risk of death, cardiovascular and renal disease seen in epidemiological studies it 
should follow that suppression and treatment of atrial fibrillation should confer a mortality benefit. 
This has as yet proved difficult to prove in randomised controlled trials however. In the AFFIRM 
study no mortality benefit was seen when comparing rate versus rhythm control although this study 
highlights the difficulty of study in AF where at any one time one third of the rate control arm were 
in sinus rhythm compared to two thirds of the rhythm control arm74. Re-analysis of AFFIRM 
highlighted the importance of anticoagulation on mortality in AF while sinus rhythm was associated 
with a mortality benefit but this was negated by the use of antiarrhythmic medications75, the 
mortality risks of which are well recognised76,77. 
 
Studies of catheter ablation for Atrial Fibrillation with a control arm of rate control have proved 
difficult to conduct for a variety of reasons. The necessary size of study to demonstrate statistical 
significance for mortality as well as the problem of randomising patients to a non-catheter ablation 
arm mean that the mortality benefit of a rhythm control strategy remains unproven outside of heart 
failure populations78,79.  
1.4 Pathophysiology of Atrial Fibrillation 
 
A universal theory for the pathophysiology of atrial fibrillation remains elusive but many of the 
theories regarding the pathophysiology of atrial fibrillation remain as relevant today as they did in 
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the early 20th century. The exact mechanism causing atrial fibrillation is complex and unclear, but it is 
widely accepted that arrhythmia onset requires a trigger and a substrate to maintain the arrhythmia.  
Over the past 100 years three main theories have persisted to explain the mechanism of onset for 
atrial fibrillation. These are: Ectopic Foci, Multiple propagating wavelets and localised re-entrant 
activity with fibrillatory conduction.  
Figure 1-1 An ECG recording made by Thomas Lewis from a patient with atrial fibrillation 
with fibrillatory “f” waves highlighted80 
 
1.4.1  Ectopic Foci 
 
Rothberger and Winterberg were the initial proponents of the theory that atrial fibrillation is 
triggered by rapid discharge at an isolated ectopic foci. Their research, published just before Thomas 
Lewis produced the first ECG showing atrial fibrillation, demonstrated atrial fibrillation triggered by a 
50Hz burst at a single location in the atrium81. However contemporaneous research into the 
mechanism of AF by Lewis82, Mayor83, Mines84 and Garrey85,86 led to the circus movement theory, 
which superseded ectopic foci theory and became the accepted mechanism for the first half of the 
twentieth century87.  
 
In 1949 doubt was cast on the generally accepted theory by Scherf and Terranova who were able to 
induce atrial tachycardia and fibrillation by applying Aconitine (a sodium channel antagonist) to the 
epicardial surface of a canine right atrial appendage88,89. This led to a number of research papers that 
backed up the ectopic foci theory, although it was debated whether the mechanism for impulse 
formation at the focus was due to repetitive discharges or localised circus movement90–93. 
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It was almost half a century later in 1998 when the ground-breaking series by Haissaguerre et al 
demonstrated an ectopic trigger for AF in the pulmonary veins that could be eliminated by focal 
ablation94. This work started a huge escalation in cardiac electrophysiology and the invasive 
treatment of AF targeting these causative triggers. 
1.4.2  Circus Movement and the Multiple Wavelet Theory 
 
The circus movement theory of AF was the accepted mechanism and widely taught as such until the 
late 1940’s after being described by Thomas Lewis in early 1920’s87,95.  The theory was generated 
from work done over the previous thirty years by a number of researchers beginning with 
Engelmann in 1896 who suggested AF was due to multiple heterotopous foci. It was Mayor in 1906 
experimenting on jellyfish and rings of muscle from the ventricles of turtles who showed that by 
applying combinations of electrical impulses a sustained electrical wave would propagate 
indefinitely in one direction83. These experiments were repeated and refined by Mines and Garry 
before being incorporated by Thomas Lewis into his circus movement theory of AF. Mines described 
the basic requirements for initiation and maintenance of re-entry to be: unidirectional conduction 
block, a core of inexcitable conduction tissue around which the wave can propagate and excitable 
tissue ahead of the wavefront84–86. 
 
Thomas Lewis’s description of the mechanism of atrial flutter and fibrillation proposed a single 
circuit generating fibrillatory activity. In atrial flutter there was a large circuit around the right atrium 
and Lewis postulated the path length around the auricle of a great vein was greater than the wave 
length and this would accurately repeat from cycle to cycle as the wave revolves around the large 
obstacle and the wavefront follows some distance behind the tail. For atrial fibrillation the circuits 
were smaller with smaller path length and shorter excitable gap. In this scenario the wavefront of 
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electrical activity follows closely behind its own tail giving rise to atrial excitation cycles that follow 
closely together and if the refractory period in the surrounding atria is shorter the propagation of 
the waves to the atria will become disorganised and lead to AF. 
 
Work in the 1940’s by Weiner and Rosenblueth further refined the circus movement theory, 
postulating the rotation around single or multiple obstacles was necessary to initiate and maintain 
atrial arrhythmia96. Gordon Moe moved things forward again. Moe’s work in the 50’s was based on 
the theory that atrial activity was totally disorganised and ‘randomly wandering wave fronts, ever 
changing in number and direction’. This led to the multiple wavelet hypothesis of AF and the first 
computer models of AF which predicted the randomness in temporal and spatial distribution of 
membrane properties which played dominant roles97,98.  
 
Allessie et al in 1985 used animal models to map the spread of excitation and AF following rapid 
atrial pacing in the presence of Acetylcholine. They demonstrated multiple propagating wavelets but 
the number needed to sustain the arrhythmia was between 4 and 6 rather than greater than 26 as 
Moe’s computer model had predicted99. The same group had previously demonstrated that 
sustained vortices of re-entry could occur in healthy tissue in the absence of an anatomical obstacle, 
a finding that went against Mines basic requirement for re-entry100. 
1.4.3 Rotor Theory 
 
Rotor theory evolved from the previous experimental work that predicted the heart could sustain 
electrical activity that rotated around a functional obstacle.  Davidenko et al first demonstrated that 
self-sustaining rotor waves could be introduced by a single premature electrical stimulus101. A rotor 
is an organizing source and driver of functional re-entry activity and these rotors can be shown to 
emit a 2D wave of excitation. Unlike the leading circle theory of fibrillation development where the 
Left Atrial Posterior Wall isolation for the treatment of Persistent AF Guy Furniss 
 37 
structural or functional obstacle is fixed, refractory and static computer models of rotors show how 
they are not fixed around an anatomical or functional point and do not have a fixed wavelength. 
They therefore pivot and rotate around a moving excitable core allowing them to drift and meander 
depending on the tissue excitability102.  
 
Rotor theory brings us back 100 years to Thomas Lewis’s initial observations that a single circuit can 
maintain and generate fibrillatory activity except rather than being waves around a ring they may be 
spiral waves around rotors. Low density mapping studies in humans using basket catheters 
reinforced this theory and suggested stable rotas as drivers of AF which could be targeted with 
ablation103–105. High-density atrial mapping studies have not supported the basket catheter mapping 
studies. Instead rotors have either not been seen106,107 or existed only briefly108,109. Further doubt 
about the role of stable rotors in the persistence of AF has been cast by the relatively poor outcomes 
of independent investigations using basket catheters to target rotors in AF ablation110,111. 
 
1.4.4 The elusive universal theory of Atrial Fibrillation 
 
After over 100 years of study in atrial fibrillation the pathophysiology remains mysterious and a 
question that will generate hypotheses for years to come. It is clear from Haisseguerres work and 
the subsequent twenty years of AF ablation that ectopic foci are key in selected patients with AF. Yet 
persistence of atrial fibrillation maintained by swirling electrical vortexes similar to the circus 
movement theory has repeatedly been shown in computer models and mapping studies. Further to 
that endo-epicardial currents have been shown to have a demonstrable role in focal activation and 
perpetuation of AF106,112. 
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The development of atrial fibrillation is caused by structural and electrical changes in the atria. These 
can be associated with co-morbidities or just as a consequence of age or genetic susceptibility. All 
the theories of atrial fibrillation may be true and co-exist occurring in some AF patients but not 
others or all AF patients at some time depending on the AF syndrome. This variety of potential 
mechanisms presents a clinical challenge to treating AF. Ablation can target triggers, substrate or 
both. However without fully understanding why AF occurs it is perhaps unsurprising that the optimal 
ablation lesion pattern is undefined.  
 
1.5 Management of atrial fibrillation 
 
 
The management of atrial fibrillation consists of two components. One is the assessment of stroke 
and thromboembolic risk with anticoagulation instituted if indicated; this is done in all patients. The 
other decision is rate or rhythm control strategy. This is where AF is either accepted or alternatively, 
in appropriate individuals, AF is suppressed or treated via drugs or catheter ablation.  
1.5.1  Thromboprophylaxis and Stroke Risk 
 
 As Atrial fibrillation increases an individual’s risk of stroke five-fold consideration of anticoagulation 
should be made in every patient. AF related strokes are often more severe and associated with 
greater mortality, morbidity and consequent costs. It has been estimated that the societal costs of 
stroke in the UK are £8.9 Billion per year and by improving AF detection and treatment significant 
public health improvements can be made with consequent reduction in stroke-related costs. The 
Imperial College Health Partners model of AF can be used to estimate AF prevalence, undiagnosed 
AF and undertreated AF for individual CCG’s (clinical commissioning groups) using publicly available 
primary care data. It can also be used to calculate the potential strokes prevented and total cost 
saved by better screening and anticoagulation.  For Somerset CCG (where I work) with a population 
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of 561,000 estimates from the calculator suggest 16.9% of AF patients are not diagnosed, 28.7% of 
those with AF have not been appropriately risk assessed, 18.7% have been risk assessed but are not 
appropriately anticoagulated and 20% are undertreated. If these care deficiencies are corrected 
reductions strokes could save over £10 million in costs over 3 years. Similar inadequacy of 
identification and screening are seen throughout the UK and Public Health England have launched a 
program to reduce the incidence of AF related stokes by 5000 in the next 5 years.  
1.5.2  Risk Scores 
 
While AF increases the risk of stroke and thromboembolism up to five-fold this is greatly influenced 
by age, sex and co-morbidity. The CHADS2VaSc score is a risk score that given an estimate of annual 
stroke risk.  
• C – Congestive Heart Failure – 1 (point) 
• H – Hypertension – 1 
• A – Age ≥ 75 – 2  
• Diabetes Mellitus – 1 
• Stroke History – 2 
• Vascular disease – 1 
• Age ≥ 65 – 1 
• Sex category - 1 
 
The CHADS2VASc score increased the accuracy of the existing CHADS score and identified a group of 
patients with a score or 0 in men of 1 in women who are truly low risk and do not require 
anticoagulation113.  The HASBLED score can be used in conjunction to estimate bleeding risk and 
identifies risk factors that can be modified114. 
 
1.5.3  Rate versus Rhythm Control 
 
The other key strand in the management of AF is a decision about rate or rhythm control. This is a 
decision about whether the focus of treatment should be to accept AF and just control the 
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ventricular rate or to prevent episodes of AF and maintain sinus rhythm.  Despite AF being 
associated with increased mortality a rhythm control strategy has not been shown to improve 
mortality outside of heart failure populations. Therefore the decision for rhythm control remains 
driven by symptoms from atrial fibrillation.   
1.5.4  Anti-Arrhythmic Medication 
 
Anti-arrhythmic drugs are given to patients with atrial fibrillation to maintain sinus rhythm.  They are 
classified by the Vaughan-Williams classification into four classes. Of these the class I drugs 
flecainide, procainamide, disopyramide the class III drug Sotalol and the class IV drug amiodarone 
are used most commonly depending on the patient characteristics and presence or absence of 
ischaemic or structural heart disease. While they can be effective, all the anti-arrhythmic drugs are 
pro-arrhythmic and carry a degree of morbidity115. They have consistently been shown to be inferior 
to catheter ablation for the prevention of AF (table 1.1) 
 
1.5.5  Direct Current Cardioversion 
 
Direct current cardioversion has been used to terminate episodes of atrial fibrillation since the 
1960s. It is simple, safe and widely available but long-term sinus rhythm is rarely achieved through 
cardioversion alone116. Generally the procedure is used for AF patients with acute haemodynamic 
instability or as a trial of sinus rhythm to assess symptomatic improvement for those in persistent 
atrial fibrillation. Elective cardioversion outcomes are worse with increasing durations of atrial 
fibrillation and larger left atrial dimensions116. Acute success of cardioversion and maintenance of 
sinus rhythm after the procedure can be improved with pre and post procedural amiodarone 
use117,118.   Patients who undergo successful cardioversion with a symptomatic improvement need 
consideration for anti-arrhythmic medication or catheter ablation. 
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1.5.6  Atrial Fibrillation Ablation 
 
 
In 1998 Michelle Hasseguire el al identified a cohort of patients with paroxysmal atrial fibrillation in 
whom spontaneous initiation of AF was mapped to triggers in the pulmonary veins which could be 
targeted by focal ablation at these sites119. This built on a previous case series120 and they then 
developed the technique of pulmonary vein isolation, demonstrating that Atrial fibrillation can be 
successfully treated by ablation. This development marked the birth of modern AF management. AF 
ablation with PVI is now the cornerstone of treatment for patients with symptomatic drug resistant 
AF and has widespread inclusion in guidelines on the management of AF121. 
 
Pulmonary vein isolation involves accessing the left atrium via an atrial trans-septal puncture and 
creating a ring of inert scar tissue encircling the pulmonary veins so the triggers of AF cannot escape 
from the pulmonary veins. The lesions can be created using several different technologies: 
Radiofrequency (RF) ablation (delivered as a series of adjoining points inside the atrium via linear or 
circular catheters that encircle the pulmonary veins), cryoablation or laser ablation via balloons 
advanced into the pulmonary veins. The ablation technique utilised to achieve PVI is at the 
discretion of the operator as no technology has been shown to be superior. In the randomised 
control trial FIRE and ICE cryoablation was non-inferior to RF ablation122.  
 
Outcomes of AF ablation for paroxysmal AF remain excellent with freedom from AF rates off anti-
arrhythmic drugs at one year greater than 70% in several studies of PVI via RF ablation or 
cryoablation123.  
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Improvements in hard endpoints such as mortality are as yet unproven for AF ablation outside of 
heart failure populations in the CASTLE AF study28.  
 
The recently published CABANA study124,125, randomised patients to AF ablation or medical therapy. 
This landmark study’s first results were presented in 2017 and no significant difference in a 
composite endpoint of death, disabling stroke, serious bleeding or cardiac arrest was seen overall. 
When re-analysed as treatment received rather than per-protocol a difference was seen. This 
analysis introduces bias as these treatments are against randomisation potentially leaving the 
comparative groups unmatched. Overall 2204 patients were randomised, 1108 to ablation and 1096 
to medical therapy however only 90.8% of those randomised to ablation received that treatment 
and 27.5% of those in the medical therapy arm received ablation. What was significant and in 
keeping with previous studies is that ablation significantly reduced AF recurrence compared to 
medical therapy. A lower than expected event rate left the trial underpowered however and this 
much anticipated study did not answer the question about AF ablation for mortality benefits. 
 
Following the 2017 ORBITA study of angioplasty which included a sham arm126, as have studies of 
renal denervation127. There have been calls for future AF ablation studies to be placebo controlled 
and include a sham arm where a fake procedure is performed128.  This would add weight to the 
benefit of AF ablation for symptomatic AF. 
 
Table 1-1 Summary of trials of AF ablation for PAF 
Trial Yr Study type Number Timeframe Ablation 
success 
 
Drug success Ablation  
complications 
RAAFT129 2005 AAD vs PVI 70 12 months 84% 37% 9% 
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APAF130 2006 AAD vs PVI 
+ mitral & 
tricuspid 
line 
198 12 months 86% 22% 1% 




112 12 months 89% 23% 5.7% 
Thermacool 
AF132 




167 12 months 66% 16% 4.9% 
STOP-AF123 2013 AAD vs PVI 
(cryoballoo
n) 
245 12 months 70% 7% 3.1% 




127 24 months 45% 28% 4.9% 


















1.5.7  Limitations of Atrial Fibrillation studies 
 
Interpreting the success rate from atrial fibrillation ablation studies can be challenging. Often the 
earlier studies are in mixed groups of paroxysmal, persistent and long-standing persistent AF 
patients. Likewise, while the lesion set is usually based around pulmonary vein isolation, additional 
lesions such as CFAE (complex fractionated atrial electrograms) or linear ablation are at the 
discretion of the operator. This can make studies in AF heterogenous and difficult to draw 
conclusions from. In addition to this, technological changes in left atrial mapping and ablation 
catheters mean that earlier studies are not always insightful when assessing modern AF ablation. 
Significant variation also exists in follow-up of AF ablation patients as the more we look for 
arrhythmia following ablation the more we are likely to find it. Time and economic constraints 
preclude regular ambulatory monitoring during follow-up or the routine implantation of loop 
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recorders. The variability in recruitment, trial design and follow-up led to international guidelines on 
research in AF134. 
 
1.5.8  Ablation for Persistent Atrial Fibrillation 
 
As AF ablation became widespread it became clear that outcomes in patients with persistent atrial 
fibrillation were inferior to those in paroxysmal AF. In longstanding persistent atrial fibrillation 
ablation outcomes are particularly poor. Additional ablation targeting non-pulmonary vein triggers 
such as complex fractionated electrograms, rotors and ganglionic plexi or additional substrate 
modification via left atrial roof, floor and mitral isthmus lines have been used in patients with 
persistent AF. Despite this increasing complexity of ablation, outcomes have not significantly 
improved and pulmonary vein isolation remains the mainstay of AF ablation. 
1.5.8.1  Additional Linear ablation 
 
The addition of linear ablation to pulmonary vein isolation is intended to reduce the risk of atrial 
arrhythmia recurrence by preventing the development of macro re-entrant flutter. The commonest 
additional lesions are a mitral isthmus line or a roof line connecting the pulmonary veins. Small 
studies by Ernst, Jais and Fassini suggested improved outcomes with linear ablation combine with 
PVI over PVI alone135–137. However linear ablation showed no benefit over PVI alone in the STAR AF II 
trial in persistent AF138. A meta-analysis of linear ablation added to PVI by Scott et al which includes 
STAR AF II showed no significant difference in arrhythmia free survival and highlighted the increased 
procedural duration and fluoroscopy time with additional ablation lesions139. 
1.5.8.2  Complex fractionated atrial electrogram ablation 
 
Complex fractionated atrial electrograms (CFAE) ablation was first described by Nademanee in 
2004140. CFAE’s were described at areas of slow conduction where wavelets rotate around pivot 
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points141. The idea behind CFAE ablation is to target areas of functional re-entry that could act as 
triggers for AF. CFAE were described by Nademanee as either140: 
1) atrial electrograms that have fractionated electrograms composed of two deflections or 
more, and/or perturbation of the baseline with continuous deflection of a prolonged 
activation complex over a 10-s recording period 
 
2) atrial electrograms with a very short cycle length (≤120 ms) averaged over a 10-s recording 
period 
 
The initial study outcomes were good in a mixed AF population (57 PAF, 64 PsAF) with 74% free from 
AF at 1 year. PVI was not performed but many of the CFAE were mapped to the pulmonary vein 
ostia. Subsequent study in a persistent AF population resulted in only 33% freedom from AF at 14 
months following a single procedure142. In the STAR AF trial CFAE ablation alone was inferior to PVI + 
CFAE143 and the addition of CFAE to PVI did not improve outcomes in persistent AF ablation in STAR 
AF II138 
1.5.8.3  Rotor ablation and FIRM mapping 
 
Great excitement was generated by the results published by Narayan et al in 2012 of a study 
comparing basket catheters and Focal Impulse and Rotor Modulation (FIRM) guided ablation with 
conventional ablation. In 92 patients, of whom 72% had persistent AF, those who underwent FIRM-
guided ablation has significantly superior freedom from AF (82.4% vs 44.9%, p <0.001)104. The long 
term outcomes were similarly impressive144. However the results have not been reproduced by 
other groups110,111 and concerns have been expressed about the generation of the rotor maps as the 
signal processing algorithms have not been made available by the manufacturer145. Currently the 
efficacy of FIRM ablation in persistent AF is unproven. 
1.5.8.4  Ganglionic Plexi Ablation 
 
The intrinsic cardiac nervous system consists of ganglionic plexi (GP) located epicardially on the 
posterior wall of the left atrium146. Ganglionic Plexi have been implicated in both the triggering and 
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perpetuation of atrial fibrillation147. Inadvertent ablation of GP during standard catheter ablation of 
atrial fibrillation may occur due to the location of GP near the pulmonary veins but it has also been 
shown that targeting GP during ablation can enhance procedural success148 with the presence of GP 
responses post AF ablation being a predictor of worse outcomes149. 
 
GP can be targeted either through anatomical maps134 or through identification of GP by high 
frequency stimulation150. A number of surgical studies have shown that freedom from AF is improved 
by epicardial targeting of GP sites151. These can be excised or ablated. In one study botulinum toxin 
injected into these sites reduced AF occurrence152,153. Active GP sites following surgical ablation are 
associated with AF recurrence154
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Figure 1-2 Anatomical map of Ganglonic Plexi (adapted from Calkins et al134) 
 
LSPV- left superior pulmonary vein, RSPV –right superior pulmonary vein, LIPV – left inferior 
pulmonary vein, RIPV right inferior pulmonary vein, IVC – inferior vena cava 
 
Permission to reproduce this image has been granted by Elsevier 
 
In catheter ablation targeting GP alone has not shown sufficient promise to be adopted widely with 
outcomes inferior to PVI155–157. However the addition of endocardial mapping and ablation of GP to 
PVI has been shown to be superior to either PVI or GP ablation alone in paroxysmal158 and persistent 
AF159. Superior outcomes in redo ablation have been shown with the addition of GP ablation when 
compared to redo PVI alone160. Improved outcomes with the addition of GP ablation to surgical AF 
ablation mean it will remain a potential adjunct to PVI for the treatment of AF151. 
 
1.6  Surgical AF ablation 
 
 
1.6.1 Surgical AF ablation techniques  
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Several techniques for surgical treatment were developed in the 1980’s, which included the left 
atrial isolation procedure, the corridor procedure, the atrial transection procedure and the maze 
procedure. Of these the Cox-Maze became the standard161.  
 
1.6.2 The Maze procedure 
 
 
First performed by James Cox in 1987, the MAZE procedure built on AF mapping and modelling 
studies by Moe98 and Allessie99 and his own research on computer and animal models of atrial 
fibrillation. As previously described, according to these model’s atrial fibrillation, once established, 
consisted of two or more large simultaneous macro re-entry circuits in the atria simultaneously. It 
was deduced that by placing the atrial lesions close together these circuits could not develop but 
dividing the atria up into small strips while treating atrial fibrillation prevented atrial activation 
during sinus rhythm. The Maze lesion set was designed to break up the atria sufficiently to prevent 
atrial fibrillation but not enough to inhibit conduction in sinus rhythm162. The lesion set divided up 
the atrium to prevent macro re-entry circuit development with a main corridor that allowed normal 
atrial conduction. A series of blind alleys off this corridor allowed conduction to all parts of the 
atrium but prevented circuit formation. Initially developed on cadaveric canine hearts it was then 
used in live animal models before the first human operation in 1987. 
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Figure 1-3 The first MAZE lesion set163  
Permission to reproduce this image has been granted by Elsevier 
The first man who underwent the MAZE remained in sinus rhythm for seven days postoperatively 
until the atrial fibrillation recurred. At this point he was commenced on digoxin and procainamide 
and reverted to sinus rhythm. This was maintained for almost twenty years despite the early 
discontinuation of procainamide due to the development of drug-induced lupus. The second patient 
who underwent a Maze procedure five months later was George Dheere, a 37-year-old pilot from 
Cyprus. He had previously undergone an atrial transection procedure, which meant the final lesion 
set was similar to the later Maze III lesion set. He developed an atypical atrial flutter shortly after 
surgery which was mapped to the mitral isthmus and successfully treated with endocardial catheter 
fulguration163.  
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1.6.3  Maze III procedure 
 
The Cox-Maze III procedure was developed from the original maze procedure following the atrial 
dysfunction and high incidence of late chronotropic incompetence that necessitated pacemaker 
implantation in the initial maze patients. A maze II procedure with a revised lesion set aimed to 
improve atrial conduction but this was a technically challenging procedure with similar drawbacks to 
the maze I. This led to the maze III procedure; also known as the “cut and sew” maze which for two 
decades was the gold standard for surgical AF ablation. Isolation of the left atrial posterior wall with 
a box lesion incorporating the pulmonary veins is key in this lesion set. 
Figure 1-4 The Modified Maze and Maze III lesion sets used in a Japanese series of 
convergent procedures (adapted from Kosakai et al164) 
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1.6.4 Outcomes from the Cox-Maze III “cut and sew” procedure 
 
The results of the Maze III procedure have been excellent. In James Cox’s original series of 112 
consecutive patients at Washington University, St Louis, late follow-up was available in 88% of 
patients in whom 96% were free of atrial fibrillation at a mean or 5.4 +/- 3.0 years and of those in 
whom 14 year follow-up was available 92% remained free from symptomatic AF with 80% off anti-
arrhythmic drugs165. Further large series at the Cleveland and Mayo clinics both demonstrated 
success rates of 90% in restoring sinus rhythm and 90% remained in sinus rhythm after 3 years 
follow-up in the Cleveland series166,167.   
 
Despite its apparent efficacy the Cox-Maze III procedure was limited by it ‘s complexity, long 
cardiopulmonary bypass duration and need for a median sternotomy. Uptake of the procedure was 
limited to patients undergoing concomitant heart surgery as it was deemed to be too invasive for 
standalone AF treatment168. 
1.6.5  The Cox-Maze IV 
 
The Cox-Maze IV procedure was designed to replicate the maze III with the use of ablative tools 
rather than via a “cut and sew” technique. This was advantageous as the lesion set was simpler and 
could be performed through a either a median sternotomy or right mini-thoracotomy for standalone 
AF surgery. The Cox-Maze IV was developed in 2002 and utilised ablation technologies to deliver the 
modified lesion set169. The simplification of the operation led to significant expansion in surgical 
atrial fibrillation ablation. Procedural time, cross-clamp time and complications such as peri-
operative stroke are reduced compared to the Cox-maze III170,171. Further reductions in morbidity 
and hospital stay are seen with the mini-thoracotomy compared to a median sternotomy 
approach172. 
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In a single centre study of over 20 years experience with the Cox-Maze III and IV by Weimar et al the 
major complication rate of the CM – III was 10% and 1% with the CM – IV, A similar rate of 
pacemaker implantation was seen with the two procedures at 8% and 7% respectively. The 30 day 
mortality rate for CM – III was 1.8% and 1% for CM IV171. 
 
Figure 1-5 Cox Maze 4 lesion set adapted from Ruaengsri et al173 
 
Permission to reproduce this image has been granted by Oxford University Press 
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Outcomes of the Cox-Maze IV are good with 5 year freedom from AF 78% on anti-arrhythmic drugs 
and 66% off AAD’s in a large series of 576 patients at Washington University. In this study there was 
no statistical difference in outcomes between paroxysmal and persistent atrial fibrillation if those 
who did not have an intact “box“ lesion set were excluded. Failure to isolate the left atrial posterior 
wall and complete a “box” was associated with worse outcomes174. In a cohort of patients with AF 
who underwent a concomitant Cox-Maze IV during coronary artery bypass grafting outcomes at 5 
years were similar175. 
 
1.6.6  Minimally invasive surgical Atrial Fibrillation ablation 
 
The use of surgical catheter ablation in the Cox-Maze IV led to minimally invasive thoracoscopic 
techniques for AF ablation that could be performed off cardio-pulmonary bypass using video 
assisted thoracoscopy (VATS).  These techniques utilise radiofrequency, microwave or hi-frequency 
ultrasound (HIFU) energies. The lesion set is based on the Cox-maze and the central lesion set 
involves isolating the pulmonary veins and left atrial posterior wall. 
 
The microwave system used in the early 2000’s was less than satisfactory with freedom from AF only 
42% at one year in a series by Pruitt176. HIFU was equally disappointing177 and radiofrequency has 
become the predominant ablation energy for minimally invasive AF ablation. Monopolar ablation 
through a unilateral thoracoscopic approach is attractive as it should in theory reduce complications 
compared to a bilateral approach with bipolar RF clamps. Freedom from AF with the monopolar 
approach has been shown to be up to 89% on ADD and 51% without178,179. 
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With bipolar radiofrequency ablation through bilateral thoracotomies freedom from AF off AAD 
varied from between 86%180 and 51%181 at one year in mixed AF populations. The heterogeneity of 
series of minimally invasive surgery make interpretation of the techniques difficult to assess. One 
head to head study has suggested a potential benefit for minimally invasive surgical ablation over 
catheter ablation but at a cost of significant increase in adverse events182.  
 
Research continues on the optimal approach for AF and surgical ablation. The multi-disciplinary 
approach of surgical and electrophysiology expertise in AF ablation led on from minimally invasive 
surgery to combine surgical and electrophysiological procedures either performed as one single 
procedure or as two separate staged procedures. Both surgical and hybrid ablation have been given 
a IIa recommendation for patients with AF in the most recent guidelines.  
 
1.7 Hybrid AF ablation 
 
The first Cox-Maze surgical technique is now 30 years old and long-term outcomes of this and the 
subsequent Cox-Maze III procedure remain excellent 161,183–185. The development of the Cox-maze IV 
technique in 2004, which could be performed without cardio-pulmonary bypass, allowed 
consequent shorter recovery times and fewer complications but failed to match the Cox-maze 
outcomes. This led to hybrid ablation techniques incorporating either simultaneous or staged 
electrophysiological study174.  
 
The heterogeneity of previous hybrid ablation series and difficulty in interpretation of their results 
has been highlighted in recent reviews186,187. At date of publication three techniques for hybrid 
ablation have been reported. These include the thoracoscopic encircling catheter, the bilateral 
clamp technique and the convergent subxiphoid pericardioscopic procedure. Of the published 
studies most are in heterogeneous populations of paroxysmal, persistent and long-standing 
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persistent patients and interpretation of outcomes needs to take this into account. For the bilateral 
clamp technique, 12 month freedom from AF symptoms off anti-arrhythmic drugs in all AF 
syndromes between 91%188 and 88.1%189. Several studies of the bilateral clamp report similar 
outcomes with less than one-year follow-up. Outcomes for persistent and long-standing persistent 
atrial fibrillation in the bilateral clamp studies are good with up to 88.2%189 and 87.7%%190 freedom 
from AF symptoms off anti-arrhythmic drugs.  
 
The previous studies of a monopolar previous iteration of the thoracoscopic encircling catheter 
produced widely differing outcomes. In Le Meir’s series of 19 patients, only 7/19 (36.8%) of all AF 
patients and 4/14 (28.6%) of persistent AF patients remained arrhythmia free at one year191. In 
comparison Bisleri et al report 40/45 (88.9%) of persistent atrial fibrillation patients remained free of 
symptomatic arrhythmia at one year. The same group had also previously reported 30 patients with 
outcomes of 87.5% remaining arrhythmia free192.  
 
There have been three published studies of the sub-xiphoid approach and all of these have been 
performed as convergent procedures. A mixed cohort of patients with different AF syndromes 
reported by Gehi et al described freedom from AF rates of 66% and 37% on and off anti-arrhythmic 
drugs193. A multicentre series in a persistent and long-standing persistent AF population reported 
52% of patients arrhythmia free off anti-arrhythmic drugs and 76% with AAD194. More recently, one 
year freedom from AF rates of 86% on anti-arrhythmic drugs and 62.2%  without has been 
described195.  
 
All the hybrid techniques have a higher complication rate than published series of catheter ablation. 
When grouped together the major complication rate could be as high as 7.4% with a mortality rate 
of 0.5%186. The unilateral VATS approach does appear to have a more favourable risk factor profile 
when compared to the bilateral VATS or sub-xiphoid approach and it may be that both of these 
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methods have excellent outcome data in the hands of experienced operators but necessitate a 
steeper learning curve. 
 
1.8 Posterior wall isolation: the “box” lesion set 
 
1.8.1 The left atrial posterior wall 
 
The posterior wall of the left atrium lies anteriorly to the oesophagus and is connected to the four 
pulmonary veins (right and left superior, right and left inferior). Embryologically the left atrial 
posterior wall is formed from the developing four pulmonary veins196.  On the epicardial surface an 
epicardial fat pad is seen which usually lies at the level of the inferior pulmonary veins197. There is a 
complex autonomic innervation into the left atrial posterior wall and anatomical studies have shown 
clusters of ganglionic plexi adjacent to the pulmonary veins in four areas.  
 
While the pulmonary veins have been clearly shown to be the predominant trigger of atrial 
fibrillation many non-pulmonary vein triggers are described and are targets for ablation. Of these 
ganglionic plexi, rotors and complex fractionated electrograms can be mapped to the left atrial 
posterior wall. Also, as previously described, it has been demonstrated that fibro-fatty infiltration of 
the area plays a role in AF development in animal models. In a 1995 study of canine models AF was 
induced by rapid atrial pacing and the shortest AF fibrillatory cycle lengths were seen at sites on the 
LAPW. These were strongly associated with sustained AF and cryoablation at these points resulted in 
AF termination in 9/11 dogs198.  Subsequent animal studies have reinforced the importance of the 
LAPW in the development and maintenance of AF199,200. The consistent presence of important rotors 
on the LAPW has also been demonstrated in humans201,202.  
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The importance of the left atrial posterior wall in animal models and in the mapping of AF triggers 
has led to this being a specific target for ablation therapies.  The theory behind left atrial posterior 
wall isolation is that by modifying atrial substrate to isolate this area in conjunction with isolation of 
the pulmonary veins a number of AF triggers are treated to stop AF development while modification 
of the posterior wall reduces the substrate that potentiates persistent atrial fibrillation. Isolation of 
the LAPW is the basis for surgical and hybrid AF ablation. 
1.8.2  The Box lesion Pattern via Catheter Ablation 
 
Prior to their landmark work on pulmonary vein isolation Hasseguire et al had attempted 
fluoroscopic guided catheter ablation for atrial fibrillation in the left atrium based on a surgical 
lesion set. The development of three-dimensional mapping technology in the late nineties allowed 
greater spacial information regarding the ablation catheter tip. This facilitated early attempts to 
isolate the pulmonary veins and left atrial posterior wall with radio-frequency203. Unfortunately the 
early 3D mapping techniques were unable to produce intact ablation lines and left atrial posterior 
wall isolation via catheter ablation was not feasible.  
 
As technologies improved, catheter ablation to isolate the posterior wall became possible and was 
demonstrated to be feasible in twenty-seven patients with persistent atrial fibrillation by Sanders et 
al204. They performed standard pulmonary vein isolation with wide antral ablation and then isolated 
the posterior wall with lines connecting the top of the superior pulmonary veins and the bottom of 
the inferior PV’s. The LAPW was checked for exit block following isolation. Isolation was successful in 
all patients but with significant additional procedural time (64 +/- 16 mins vs 199 +/-46 mins). 
Posterior wall isolation terminated atrial fibrillation in 19% of patients. At 21 +/- 5 months of follow-
up 63% remained in sinus rhythm.  12 of the 27 patient remained in sinus rhythm off antiarrhythmic 
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drugs after one procedure while a further 4 patients required a second procedure to isolate the 
LAPW204.  
 
Lim et al again demonstrated the feasibility of electrical isolation of the pulmonary veins and 
posterior left atrium but this time via a single continuous ring of radiofrequency lesions in a 
consecutive series of 100 patients. The cohort of patients were of mixed atrial fibrillation syndromes 
and two-thirds were paroxysmal. 46 patients had recurrence of either atrial fibrillation or atrial 
flutter and all patients with recurrence of atrial fibrillation who were re-studied had evidence of 
LAPW reconnection. Recurrence of other atrial arrhythmias such as left atrial flutter was often seen 
due to macroreentry involving discontinuity in linear lesions205.  
 
In 2009 Tambororero et al studied 120 patients with atrial fibrillation (two-thirds paroxysmal) 
bought forward for catheter ablation. They were divided into two matched groups. A lesion set 
consisting of pulmonary vein isolation, mitral isthmus line and roof line was compared with a group 
where an additional line connecting the inferior aspect of the two inferior PV’s was created to isolate 
the LAPW. After a mean follow-up of 10 +/- 4 months there was no significant difference in AF 
recurrence in both groups (40% vs 38%) or left atrial flutter (5% vs 7%). The authors concluded that 
left atrial posterior wall isolation did not increase the success rate of circumferential pulmonary vein 
isolation although it is unclear how successful LAPWI was and how complete the lesion set was206.  
 
Several other studies to isolate the LAPW through a single ring to create the box lesion-set have 
been limited by failure to achieve a complete lesion set or concerns over ablation on the posterior 
wall and the risk of oesophageal injury. However these have been in mixed groups of patients with 
predominantly paroxysmal atrial fibrillation and it is perhaps unsurprising that the addition of 
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posterior left atrial wall isolation adds little to pulmonary vein isolation in paroxysmal atrial 
fibrillation when outcomes of AF ablation with PVI in PAF are good (table 1-2).  
 
Currently the evidence base for catheter ablation with LAPWI in persistent AF is limited and the 
outcomes from some of the early studies may be indicative of technological weakness in providing 
complete posterior wall isolation. Advances in contact force sensing catheters and 3D mapping 
mean later trials have shown advantages over PVI in persistent AF207–209. Further larger studies are 
needed but as LAPWI was not one of the STAR AF II lesions the question about it’s role in persistent 
AF ablation remains unanswered. 
Table 1-2 Summary of trials of LAPW isolation for AF 
Trial Methods AF  
syndrome 







Consecutive series PsAF + LsPsAF 27 24 months 63% N/A all 
Kumagai210 
2007 
Consecutive series PAF 91 13 months 90% N/A 90% 
Lim205 
2008 
Consecutive series of 
patients undergoing 
LAPWI 
PAF, PsAF + LsPsAF 100 12 months 54%  
N/A 
All 34 patients  
had redo  




PVI + roof line vs 
LAPWI 
PAF, PSAF + LsPsAF 120 10 months PVI + roof 47% 
LAPWI – 45% 
P = 0.9 Not stated 
Yamaguchi211 
2010 
LAPWI PAF + PsAF 92 12 months 83% N/A 100% 
Chilukuri212 
2011 
LAPWI vs PVI PAF + PsAF 29  12 months LAPWI – 25% 
PVI – 15% 
P = 0.44 19% 
Lim213 
2012 
LAPWI vs PVI (+MIL 
in halg of each) 
PAF, PSAF + LsPsAF 220  24 months AF free 
-LAPWI –74% 
-PVI – 49% 
OAT free 
- LAPWI–67% 
 -PVI – 64% 
Arrhythmia free 
-LAPWI – 52% 
-PVI – 48% 
P = 0.07 109/110 patients 




LAPWI vs PVI PAF + PsAF 80 12 months LAPWI – 58% 




Consecutive series PSAF + LsPsAF 25 16 months 72% N/A 100% 
O’Neil216 
2015 
Consecutive series PsAF (72%) + PAF 100 12 months 75% arrhythmia 
free 




LAPWI vs PVI + Lines PsAF 120 12 months LAPWI – 83% 




LAPWI (age <75 vs 
age ≥75) 





LAPWI via catheter 
vs LAPWI by hybrid 
(non-randomised) 
PSAF + PAF 57 (30 
catheter, 27 
hybrid) 
12 months 56% of total cohort ns 23% via catheter 
52% via hybrid 
Bai209 
2016 
LAPWI vs PVI PsAF 52 (32 LAPWI, 
20 PVI) 
36 months LAPWI  
-1yr – 65% 
-2yr – 50% 
-3yr – 40% 
PVI 
-1yr – 20% 
-2yr – 15% 
-3yr – 10% 
P<0.01 Second procedure 




PVI vs LAPWI guided 
by PW scar 
PsAF 141 12 months LAPWI – 80% 





LAPWI +/- adenosine 
post ablation 




1.9 Comparison of Surgical and Catheter approaches and Lesion sets 
 
1.9.1 Surgical vs Catheter Ablation 
 
Comparisons of surgical and catheter ablation for atrial fibrillation have pointed towards superior 
outcomes with regard to freedom from atrial fibrillation with surgical ablation but at a cost of 
increased complications. The FAST study182, published in 2012, was the first randomised trial to 
compare surgical and catheter ablation in 123 patients with paroxysmal or persistent AF. Most 
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patients had undergone an unsuccessful catheter ablation previously and lesion sets varied between 
both arms. The catheter ablation technique varied between study sites from PVI only to PVI with 
lines. Bipolar clamps were used for PVI in the surgical group but there was variation in additional 
lesions and GP excision between centres. Freedom from AF at one year was significantly higher in 
the surgical group (65.6% vs 36.5%, p=0.0022, off AAD and 78.7% vs 42.9%, P<0.0001, on AAD) 
however this came at a cost of complications. The serious adverse event rate during the 12-month 
study period was 34.4% in the surgical group versus 15.9% in the catheter group (p=0.027), which 
was primarily driven by procedural adverse events, 23% vs 3.2% (p=0.001). Surgical procedural 
complications included 6 pneumothoraces, one haemothorax and two pacemaker implants.  
 
A meta-analysis of minimally invasive surgery versus catheter ablation in 2016 by Phan et al 
indicated improved freedom from AF with surgical ablation but increased procedural complications 
driven by pleural effusions and pneumothorax220. More recently the CASA AF study in longstanding 
persistent AF has shown similar findings221. A further study with implantable loop recorder follow-up 
is ongoing222 and will be important as outcomes in these patients with catheter ablation alone are 
poor. 
1.9.2 Hybrid vs Catheter AF ablation 
 
A combined sub-xiphisternal epicardial ablation using the Ncontact System (Atricure Inc) has been 
compared to catheter ablation alone in paroxysmal, Persistent and longstanding persistent AF 
patients. Freedom from AF was greater in the hybrid group compared to PVI alone but in a study of 
longstanding persistent AF no difference was seen between hybrid ablation and extensive left atrial 
endocardial ablation. In both studies pre-procedural complications were greater in the hybrid 
groups223,224. A retrospective study of the technique in persistent AF by Kress et al also reported 
similar outcomes225.  A randomised prospective study of a two-stage hybrid approach and catheter 
ablation only has not been performed. 
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The optimal ablation treatment of persistent atrial fibrillation (AF) remains unclear and the optimal 
technique of surgical (epicardial), catheter (endocardial) or hybrid (both) ablation is yet to be 
established. The initial experience with hybrid AF ablation involving PVI and left atrial posterior wall 
isolation has shown promising results with regard to freedom from AF. Newer surgical techniques 
have recently become available that enable isolation of the posterior wall with the so-called ‘box 
lesion-set’6. The box-lesion set has shown promise in previous studies with failure related to the 
technical difficulty in making a complete lesion set7, 8,9.  
 
Recent advances in both surgical and catheter ablation techniques are hypothesized to improve the 
success rate of ablation by increasing the likelihood of complete posterior left atrial isolation via a 
box-lesion set. This MD will involve work contributing to and informing the development of a head-
to-head trial of surgical and catheter ablation of AF and answer mechanistic questions about left 
atrial ablation.  
 
I aim to study hybrid and catheter ablation techniques for posterior wall isolation addressing the 
following questions: 
o Does Posterior Left Atrial Wall Isolation in patients with persistent atrial 
fibrillation provide longstanding freedom from Atrial Fibrillation? 
o Can non-invasive assessment of posterior wall isolation be used to predict the 
success of surgical and catheter ablation for atrial fibrillation? 
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o Does Epicardial ablation provide lasting modification of the cardiac autonomic 
nervous system? 
o Can the development of new catheter technologies confer greater stability and 
contact in left atrial ablation? 
 
These 4 projects will answer questions that will allow us to design a further trial (not part of this MD 
but following from the work in this MD thesis) that will be a randomised comparison of Left Atrial 
Posterior Wall isolation by hybrid ablation versus catheter ablation only.   
The four projects need to be completed before this trial can be designed as they will provide data 
necessary for: 
1) Performing power calculations on projected outcome measures, 
2) Planning clinical stages in the patient pathway in the trial (such as non-invasive assessment 
of posterior wall isolation following the surgical procedure, but prior to second stage 
catheter ablation), 
3) Understanding the relative contribution of targeted ganglionic plexi ablation versus electrical 
isolation in achieving successful therapy, and  
4) Which catheter apparatus is likely to give the best results in the catheter ablation only 
approach? 
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2 Chapter 2 - Catheter Ablation of Atrial Fibrillation with Left Atrial 




Aims: To determine the acute success rate and long-term freedom from atrial fibrillation in patients 
who undergo catheter ablation for atrial fibrillation with the lesion set of left atrial posterior wall 
isolation. 
Methods: This was a partially retrospective study of patients who had undergone left atrial posterior 
wall (LAPW) isolation via catheter for symptomatic persistent atrial fibrillation or recurrent AF 
following pulmonary vein isolation. Procedural success and complications were recorded either 
retrospectively from patients notes or prospectively at the time of procedure. Successful LAPW 
isolation was documented as were procedural complications. Follow-up was via telephone or face-
to-face clinics at 4 months 12 months and 24 months post procedure. 7-day holter monitoring was 
performed at 12 months and 24 months. 
Results: Thirty-three patients (29M, 4F) underwent LAPWI. 25 had PsAF and 8 PAF. LAPWI was 
successful in 70% (23/33). The single procedural complication was tamponade requiring 
pericardiocentesis.  
After a median of 24 months follow-up (IQR 16-24) 20 patients were free from arrhythmia 
recurrence (60%). 19 (58%) off antiarrhythmic drugs. Having a complete lesion set with confirmed 
LAPW isolation was associated with better outcomes. 17/23 (74%) remained free of atrial 
arrhythmia compared to 3/10 (30%) where LAPW isolation was not seen (p=0.026) and median 
arrhythmia free duration was 24 months (16-24) vs 12 months (11-15) respectively (p=0.017).  
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Conclusions: Left atrial posterior wall isolation is feasible with a limited complication rate. Outcomes 
are significantly improved where successful left atrial posterior wall isolation is confirmed with 
entrance and exit block. When the lesion set is complete freedom from atrial arrhythmia appears 
superior to other lesion sets but randomised comparison in larger trials are needed.  




To determine the acute success rate and long-term freedom from atrial fibrillation in patients who 




Left atrial posterior wall isolation and its development as a technique in the ablation of atrial 
fibrillation is described at length in Chapter 1. The technique has been used as a treatment for atrial 
fibrillation at Derriford Hospital for over 10 years. The lesion pattern was initially used surgically in 
HIFU ablations but shortly after that catheter technologies were utilised to create the same lesion 
set. This was decided on following the initial promising studies described in chapter 1 with the aim of 
improving outcomes from ablation in persistent AF.  
 
In the first catheter ablation cases the lesions were created with the Ablation Frontiers PVAC/TVAC 
system (Medtronic Inc, Minneapolis, USA) however rigorous testing for electrical isolation proved 
difficult. It wasn’t until 3D mapping systems were adopted for the lesion pattern that electrical 
isolation for the posterior left atrium could be confidently predicted. This chapter relates to those 




Patients with symptomatic persistent atrial fibrillation refractory to anti-arrhythmic medications 
referred to the electrophysiological service at Derriford Hospital Plymouth are considered for 
catheter ablation. Those with continuous AF durations of less than 12 months who do not have 
severely enlarged left atria are offered catheter ablation with pulmonary vein isolation plus left atrial 
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posterior wall isolation. Patients with unfavourable characteristics for catheter ablation may be 
considered for a two-stage hybrid AF ablation (chapter 3). Left atrial posterior wall isolation via 
catheter ablation is also considered for those patients who have had recurrent symptomatic atrial 
fibrillation following previous ablations.  
 
In this partially retrospective observation study of clinical practice we looked at all patients who had 
undergone left atrial posterior wall isolation via catheter between 2012 and the end of 2016. For the 
patients who had previously undergone the procedure baseline demographics and ablation details 
were obtained from the medical notes with 7-day ambulatory monitoring obtained from the medical 
notes or offered again if patients had not undergone sufficient follow-up. 
 
Patients from 2014 were followed-up prospectively with demographic and ablation details 
documented at the time of procedure. Standard follow-up was then with ECG’s and clinical follow-up 
at four, twelve and twenty-four months. Seven-day ambulatory loop monitoring was performed at 
12 and 24 months with further clinical review guided by individual patients symptoms.  
 
As this was an audit of standard clinical practice formal ethical approval was not sought. 
2.4.1 Catheter Ablation  
 
All catheter ablation patients undergo radio-frequency ablation under general anaesthesia. Access is 
via the right femoral vein and right subclavian or internal jugular vein with placement of decapolar 
catheters in the coronary sinus and the right atrium. 
 
Atrial trans-septal puncture is performed under fluoroscopic guidance using standard orthogonal 
views and unfractionated heparin is given to maintain an activated coagulation time of greater than 
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300s. SL1 and Agilis sheaths (St Jude Medical, St. Paul, Minnesota, USA) are passed through the same 
aperture in the interatrial septum to give access to the left atrial chamber. If the patient is in atrial 
fibrillation, we cardiovert to sinus rhythm as we have found voltage mapping to be inconsistent in 
atrial fibrillation; sinus or paced rhythm permits propagation mapping. Mapping and ablation is 
performed using the Velocity/Precision system (St Jude Medical St. Paul, Minnesota, USA) and the 
Tacticath Quartz (St Jude Medical, St. Paul, Minnesota, USA) contact force sensing catheter. Three 
early patients in this series underwent mapping and ablation using the CARTO system (Biosense 
Webster, Diamond Bar, California, USA). 
 
A three-dimensional voltage map of the left atrium is created using the St Jude Velocity/Precision 
system and an AFOCUS II catheter (St Jude Medical, St. Paul, Minnesota, USA). Standard settings are 
between 0.1 mV and 0.13 mV (grey colour scale) to 0.5 mV (purple colour scale) with healthy tissue 
identified by areas of higher voltage and areas of low electrical amplitude indicating scar.. 
Pulmonary vein isolation is performed first by encircling the two pairs of veins using 25 Watts on the 
left atrial posterior wall with a 15 second maximum duration at any one site and 30-35 Watts 
elsewhere aiming for LSI of 5.5 to 6.0.  After confirmation of pulmonary vein isolation with entry and 
exit block, two lines of closely placed point-by-point lesions were then performed. The first linking 
the antero-superior margins of the two regions to form the roof line and the second, a curved line of 
lesions from the inferior margin of the left inferior pulmonary vein to the inferior margin of the right 
inferior pulmonary vein across the floor of the left atrium, curving away from the posterior wall, to 
form the floor line.  
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Figure 2-1 Left atrial posterior wall isolation (ablation lines shown by red dots) 
 
 
Left atrial posterior wall isolation is confirmed by entrance and exit block into and out of the left 
atrial posterior wall and by demonstration of pacing and capture within the isolated area without 
conduction to the rest of the atria. Evidence of block is re-checked following adenosine 
administration sufficient to provoke transient complete heart block. If the veins and posterior wall of 
the left atrium remain isolated, no further ablation is required.  
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Figure 2-2 Confirmation of Left atrial posterior wall exit block. Pacing above the resting 
heart rate on the Tacticath ablation catheter inside the LAPW fails to capture the rest of 
the atrium which is beating independently. Capture within the posterior wall is seen on 
the A-FOCUS II mapping catheter 
 
 
Post procedure, all patients are prescribed one month of proton-pump inhibitors as part of the 
oesophageal protection protocol. 
2.4.2 Follow-up 
 
Patients who were included in the study prospectively were offered telephone follow-up with a 
standard ECG at 4 months and face-to-face follow-up with seven-day holter monitors at 12 and 24 
months. Further follow-up and monitoring was driven by symptoms.  
 
For the retrospective patient’s notes, previous letters and redo procedures were looked at to 
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document any recurrence of symptoms or documented atrial arrhythmia. Patients were telephoned 
for symptom assessment at 12 months and 24 months with seven-day holter monitoring at the same 
time. If the procedure was greater than 24 months prior to the start of the trial the patients had a 
telephone assessment of symptoms and a single seven-day monitor.  
 
We aimed to report on the acute success of left atrial posterior wall ablation, time to atrial 
arrhythmia recurrence and any complications.  
2.5 Results 
 
Between October 2012 and November 2016 thirty-three patients underwent left atrial posterior wall 
isolation. The baseline characteristics are listed in the table below.  
 
Table 2-1 Summary of baseline characteristics of patients undergoing LAPW isolation for 
AF 
Baseline Characteristics Median value (Interquartile Range) 
Age 62.5 (52.75-70) 
Sex 29 Male, 4 Female 
LA AP Diameter 40mm (35-45) 
Ejection Fraction 55% (50-55) 
CHADsVASc Score 1 (0-1) 
Continuous AF duration 8 months (2-12) 
Previous Ablation 20/33 (61%) 
AF Syndrome PAF 8 (24%), PsAF 25 (76%) 
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Twenty-five of the thirty-three patients had persistent atrial fibrillation and twenty of the 
procedures were redo ablations. Following the ablation procedure the posterior wall was isolated 
with confirmed entrance and exit block in twenty-three patients (70%). All patients were discharged 
in sinus rhythm. After a median of 24 months follow-up (IQR 16-24) 20 patients were free from 
arrhythmia recurrence (60%). 19 (58%) off antiarrhythmic drugs. 
 
Better outcomes from ablation were associated with successful left atrial posterior wall isolation. In 
the group who had the LAPW successfully isolated with confirmed entrance and exit block at the end 
of the ablation 17/23 (74%) remained free of atrial arrhythmia compared to 3/10 (30%) in whom 
entrance and exit block from the LAPW was not seen (p=0.026). Freedom from atrial arrhythmia was 
also significantly longer in the twenty-three patients with confirmed LAPW isolation at the end of the 
ablation compared to those in whom LAPW isolation was not possible; 24 months (16-24) vs 12 
months (11-15) respectively (p=0.017).  
 
There were twenty-five patients with persistent atrial fibrillation who underwent LAPWI and, of 
these, isolation was confirmed following ablation in 19 (76%). Sixteen of twenty-five (64%) were free 
of atrial arrhythmia at the end of the follow-up period.  
 
Of the eight patients with paroxysmal atrial fibrillation only 4/8 patients (50%) had successful left 
atrial posterior wall isolation. Recurrence of AF occurred in 4/8 patients (50%), 3 of who had 
unsuccessful LAPWI.  
 
Successful left atrial posterior wall isolation was numerically fewer in the 20 patients who had 
undergone previous AF ablation than those who had not; 13/20 (65%) vs 10/13 (77%) although this 
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was not statistically significant (p=0.472).  There was no significant difference in freedom from atrial 




One complication of a tamponade requiring pericardiocentesis occurred following the ablation 
procedures. No other complications were seen, and no oesophageal complications were noted per-
procedurally or during the follow-up period. 
2.6 Discussion 
 
In this single centre series of left atrial posterior wall isolation for the treatment of atrial fibrillation 
the two-year freedom from atrial arrhythmia was 60%. The procedure appears to be safe with only 
one complication seen in this cohort of patients. Of those patients with persistent atrial fibrillation, 
freedom from atrial arrhythmia was 64% and this is favourable compared to the STAR AF II lesions138 
where the addition of linear or CFAE ablation did not improve outcomes compared to pulmonary 
vein isolation alone. It is important to note that left atrial posterior wall isolation was not included as 
a lesion set in STAR AF II.  
 
The benefit of LAPWI over PVI in previous studies is variable with no statistically significant 
difference seen in studies on mixed groups of AF patients by Tamborero206, Chilukuri212, Lim213 and 
Sohns214. In more recent studies in persistent AF patients Bai209, Cutler208 and Kim207 have reported 
improved outcomes of the lesion pattern compared to pulmonary vein isolation alone.  It is possible 
that in these later studies technological improvements in AF ablation equipment such as mapping 
software and contact force catheters may have resulted in better outcomes.  
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In this series successful left atrial posterior wall isolation with confirmed entrance and exit block at 
the end of the ablation procedure made a significant difference to outcomes. It has previously been 
shown in surgical AF series of LAPWI that enduring posterior wall isolation is associated with 
improved outcomes226. The rate of confirmed LAPWI in the series is in keeping with other published 
studies where rates of confirmed LAPWI vary from between 19-100%211,212. The wide variability in 
quoted LAPWI outcomes is likely a reflection of ablation technology and the rigor of testing for 
entrance and exit block into and out of the LAPW. In many of these studies it is unclear as to how 
this was confirmed and in some studies rates are not quoted.  In the largest study of this lesion 
pattern using modern ablation technology by Higuchi et al, 229 patients were enrolled and 
successful LAPWI was achieved in 76%217. This is equivalent to the rate of successful LAPWI in this 
series. 
 
Confirmed left atrial posterior wall isolation is clearly an important factor determining outcomes and 
the administration of adenosine has been shown to highlight reconnections. Mcllenan et al have 
demonstrated that adenosine administration can unmask connections into the LAPW in 17% of cases 
and improve single procedure success219.  Reconnections into the LAPW are likely to influence 
outcomes and arrhythmia recurrences. Bai et al repeated the electrophysiological study in all 
patients who had undergone LAPWI at three months. In the first ablation procedure all 32 patients 
achieved LAPWI but at the repeat study only 20 (63%) had an intact lesion set209. Reconnections into 
the pulmonary veins is an obstacle to long term success of PVI and routine re-study and ablation of 
re-connections improves outcomes in paroxysmal atrial fibrillation227,228. Given the difficulty of 
achieving confirmed LAPWI future study protocols could mandate a second electrophysiological 
study and ablation after the three-month blanking period thereby maximising the chances of 
achieving a durable lesion pattern and gaining maximum benefit for it.  
 




This study was a mixed retrospective and prospective audit of clinical practice in a mixed cohort of 
atrial fibrillation patients. Both persistent and paroxysmal atrial fibrillation patients were included 
and many patients had undergone previous ablations. It is therefore not possible to draw 
conclusions about the benefit of the lesion set in paroxysmal or persistent AF or to compare against 
alternative ablation approaches. As a database of consecutive cases inherent biases may exist in 
patient selection and choice of ablation approach.  
 
Data collection was also limited to that which was available in the medical notes or on hospital 
computer systems. While we aimed for ECG’s and ambulatory monitoring at the pre-specified time 
points this was not always performed in the retrospective cases due to non-attendance and in this 
case the outcomes were determined by telephone calls and ECG’s. Even with follow-up limited to 4, 
12 and 24 months arrhythmia recurrences may have been missed although it is likely that 
symptomatic arrhythmia recurrence would have been apparent in the medical notes.  
 
I was unable to do any detailed study of the raw velocity data and draw any conclusions from the 3D 
maps and propagation maps that were generated due to a large data loss. This meant I could only 
rely on procedure reports, letters and notes for the results. Had this information been available a 
number of questions could have been addressed regarding scar mapping and outcomes. These 
include: why LAPWI was more difficult in the redo PAF group than the PsAF group? What role did the 
LAPW play in these patients and what technical factors prevented an intact lesion set? 
 
 




Left atrial posterior wall isolation is feasible in the majority of cases with a low complication rate. 
Outcomes are significantly improved where successful left atrial posterior wall isolation is confirmed 
with entrance and exit block. In persistent atrial fibrillation freedom from atrial arrhythmia appears 
superior to the STAR AF lesion sets when left atrial posterior wall isolation is confirmed with 
entrance and exit block. Randomised comparisons in larger trials are needed.  
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Background: Treatment of long-standing persistent Atrial Fibrillation (LsPsAF) remains challenging, 
with catheter ablation outcomes inferior to those for paroxysmal atrial fibrillation, and the optimal 
ablative approach is unclear. European guidelines suggest a role for Hybrid AF ablation. We describe 
the medium-term follow-up of patients undergoing non-concomitant hybrid AF ablation. 
Methods: Patients with LsPsAF (continuous AF duration greater than one year) are offered non-
concomitant hybrid ablation to isolate the Left Atrial Posterior Wall (LAPW) following an AF Heart 
team discussion. Patients first undergo unilateral video assisted thoracoscopic (VATS) epicardial 
ablation with subsequent electrophysiological study (EPS) and ablation to complete LAPW isolation 
and add a cavo-tricuspid isthmus ablation after a minimum of two months. Follow-up is via clinical 
review at 4, 12 and 24 months with 7-day ambulatory ECG monitoring at 12 and 24 months. 
Results: 57 patients with symptomatic LsPsAF have undergone the VATS procedure; two were 
abandoned due to pericardial adhesions. Conversion to open thoracotomy was necessary in two 
patients and one patient had a fatal CVA 24 hours post-operatively. Forty-nine patients have 
undergone both stages and 40 are post the blanking period with a median follow-up of 20 months 
(IQR 12-25.5). 57% of these are free of any atrial arrhythmia recurrence off anti-arrhythmic drugs. 
There has been a significant reduction in arrhythmia burden; currently 82.5% are in sinus rhythm 
(70% off AAD). 
Of those with over 1 year of follow up, 87.5% are currently in sinus rhythm. 
 
Left Atrial Posterior Wall isolation for the treatment of Persistent AF Guy Furniss 
 78 
Conclusions: Following 2 stage non-concomitant hybrid ablation, 57 percent of LsPsAF patients are 
free of arrhythmia recurrence off anti-arrhythmic drugs .  82.5% are currently in SR (70% off AAD). 
This is superior to published outcomes of catheter ablation in LsPsAF. Care is required to avoid right 
phrenic nerve injury.  Further study is required to determine long-term outcomes and to compare 
with alternative techniques. 
  




Treatment of atrial fibrillation (AF) via catheter ablation has consistently been shown to be superior 
to treatment with anti-arrhythmic medication alone and this is reflected in contemporary 
guidelines229,230. Outcomes for persistent AF ablation are inferior to those in PAF231 and are not 
improved by the addition of roof and mitral isthmus lines or the targeting of complex fractionated 
electrograms (CFAE)138. Outcomes for patients with long-standing persistent atrial fibrillation 
(continuous AF duration of greater the 12 months) are even worse232.  
 
Surgical treatment for AF has been available for almost 25 years in the form of the Cox-MAZE 
procedure. Yet despite good outcome data174 from the procedure, its complexity has limited 
widespread use185. Surgical AF ablation has been revived by the development of minimally invasive 
techniques either as standalone procedures or as part of hybrid ablation in combination with 
catheter ablation. Initial non-randomised published data in mixed AF populations reported variable 
success rates of between 37%-90% freedom from AF at one year for all AF types and 28-80% free 
from AF in those with persistent atrial fibrillation191,192. Recently surgical and hybrid ablation 
techniques have been given a IIa recommendation in the latest ESC guidelines for the management 
of atrial fibrillation229. 
We describe our single centre experience of non-concomitant staged hybrid ablation for long-





3.3.1 The Hybrid Atrial Fibrillation Pathway and AF Heart team 
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All symptomatic patients with persistent atrial fibrillation and characteristics unfavourable for 
standard catheter ablation alone (such as continuous AF duration of longer than one year, increased 
BMI, enlarged left atrium or previous failed catheter ablations) are referred to the AF heart team to 
be considered for hybrid AF ablation (surgical VATS procedure followed by catheter ablation after 
greater than two months). Each case is discussed individually with review of symptoms, cardiac 
investigations (including cardiac CT and/or invasive angiography) and co-morbidities. An individual 
strategy for each patient is formulated that may include offering catheter ablation, hybrid ablation 
or medical management with rate control only.   
 
Those suitable for hybrid ablation are reviewed in a cardiac surgery clinic before being listed for the 
first stage procedure. Patients are informed that in situations where there is left atrial appendage 
thrombus or significant pericardial adhesions the procedure may be converted to an open 
sternotomy if required. 
3.3.2 The surgical 1st stage 
 
All patients have CT coronary angiography preoperatively to assess their cardiac anatomy and 
eliminate coronary artery disease. Patients undergo surgery partially anticoagulated (INR ≈ 1.8) or 
after 48 hours off DOAC (Direct Oral Anti-coagulant). Following induction of anaesthesia, pre-
procedural transoesophageal echocardiogram is undertaken to exclude left atrial appendage 
thrombus.  
 
The operative procedure for monolateral thoroscopic AF ablation is described in detail in the 
literature by Bisleri and Muneretto233. The patient is placed in a supine position and the patient is 
draped in traditional fashion as if for a bilateral thoroscopic procedure. The third, fourth and fifth 
intracostal spaces of the right thorax are marked for port positioning. The camera port is positioned 
at the level of the fourth intercostal space on the anterior axillary line whereas the other ports are 
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positioned slightly more anteriorly in the third and fifth intercostal spaces. Once marked the patient 
is positioned 30 degrees towards the left decubitus, the right lung is deflated and the three 10mm 
ports are placed. 
 
The pericardium is opened longitudinally 1 to 2 cm above the phrenic nerve and a wide dissection of 
the transverse sinus is performed using an endopeanut blunt dissector. A pericardial reflection 
between the inferior vena cava and right inferior pulmonary vein of the oblique sinus is then 
created. Suction assisted, mono and bi-polar epicardial ablation is performed after removal of 
epicardial fat and administration of heparin to produce a box lesion isolating the posterior left 
atrium and the four pulmonary veins. The autonomic ganglia on the right are ablated or excised 
following high frequency stimulation to identify sites of vagal response.  
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Figure 3-1. Panel A – Ports are introduced in the right thorax. Panel B – The pericardium is 
dissected and the Cobra Fusion Ablation device is introduced. Panel C – The Cobra Fusion 
is passed around the pulmonary veins to encircle the left atrial posterior wall   
 
With experience the surgical ablation technique has evolved at Derriford. Initially three, but now up 
to eight cycles of mono and bipolar radiofrequency ablation are performed following an increasingly 
aggressive removal of epicardial fat. The temperature-controlled Fusion ablation system (cycling up 
to 150W to deliver 70oC to tissue) and the presence or absence of left atrial posterior wall 
conduction block following the ablation (documented by intra-operative pacing within the isolation 
zone post DCCV) determine the number of cycles of ablation.  
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Patients go to the ward and are started on a DOAC (Dabigatran) on the evening of the surgery. The 
patients are mobilised the day after surgery and usual discharge is 48 hours postoperatively. 
3.3.3 The electrophysiological second stage 
 
The second stage procedure is performed a minimum of 8 weeks following the epicardial surgical 
ablation to allow time for conduction to recover at any non-permanent sections of the surgical 
ablation line. Until now anticoagulation has been discontinued 36 hours prior to the procedure if 
patients are on a DOAC, or, if on Warfarin, the procedure is performed with the drug uninterrupted 
and an INR of 2.0-2.5. The study is performed under a general anaesthetic via vascular access from 
the right femoral ± right subclavian/internal jugular veins. The technique for electrophysiological 
study and left atrial posterior wall isolation has been described in Chapter 2. In addition to LAPWI a 
cavo-tricuspid isthmus line is performed in all patients. 
 
If the ‘box’ lesion created by the Cobra Fusion device is not electrically intact, further ablation is 
performed, guided by the initial voltage map and propagation maps. Gaps identified in the ablation 
lines are closed by irrigated radiofrequency ablation lesions delivered with a Tacticath Quartz (St 
Jude Medical, St. Paul, Minnesota, USA) contact force sensing catheter achieving target levels of 
minimal contact force (greater that 1g above baseline and mean force greater than 10g), optimal 
stability and force-time integral appropriate for the lesion position. Precise identification of the 
position of residual electrical connection across the surgical line of block is achieved by placing the 
AFOCUS II mapping catheter against the left atrial posterior wall, close to areas identified as 
defective, and using the earliest electrical signals seen at a particular pole of the mapping catheter 
to guide RF lesion delivery. Propagation mapping in sinus rhythm is also used to identify areas of 
breakthrough in the surgical lines. Ablation is delivered with 25 Watts on the left atrial posterior wall 
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and 30-35 Watts elsewhere. Adenosine is administered and lines of block are re-checked at the end 
of the case. 
 
Figure 3-2 The non-concomitant Hybrid Ablation process involves an initial surgical 




Rarely, an atypical atrial flutter persists after left atrial posterior wall isolation. Propagation mapping 
may indicate the need for additional linear ablation such as a mitral isthmus line to terminate the 
flutter. A mitral isthmus line is not part of our standard lesion set.  
 
Left Atrial Posterior Wall isolation for the treatment of Persistent AF Guy Furniss 
 85 
All patients are prescribed one month of proton-pump inhibitors as part of the oesophageal 
protection protocol post-procedure.  
3.3.4 Follow-up 
 
Patients who undergo hybrid ablation for atrial fibrillation are followed-up at four months; one year 
and two years post the electrophysiological second stage. This includes an assessment of symptoms 
and resting ECG at four months, 12 months and two years with seven-day ambulatory monitoring at 
one and two years. Patients are asked to undertake ECG documentation at the time of any 
symptoms outside these times and to send in the ECGs obtained. 
 
In this study, we report time to first documented episode of atrial arrhythmia, defined as lasting at 
least 30 seconds on monitoring, following the 3-month blanking period after the second stage 
electrophysiology procedure and the prevalence of sinus rhythm at time of analysis and for patients 
over one year following both stages.  
3.4 Results 
 
Ninety patients entered the pathway between 2013 and mid 2017. Of these, sixty-four were deemed 
suitable for hybrid ablation following MDT discussion and clinic review. Fifty-seven patients have 
undergone a VATS procedure. Two patients had extensive pericardial adhesions so the procedure 
was abandoned, these patients had not consented to sternotomy. In two further patients, the 
surgery was converted to planned sternotomy. This was to facilitate pericardial access due to lung 
adhesions in one case and to allow for left atrial appendage occlusion due to presence of left atrial 
appendage thrombus identified on transoesophageal echocardiography in the other. One patient 
had a fatal CVA 24 hours post op. Fifty-four patients have so far been referred on for the second 
stage (patient characteristics are shown in Table 3.1) and 49 patients have undergone second stage, 
a median of 156 days post-surgery. The results and outcome data in this paper refer to the cohort 
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who have completed both stages. All statistical analysis is performed using ‘R’ version 3.2.2 (C. 2015. 
The R Foundation for Statistical Computing) 
 
Table 3-1 Summary of demographics and clinical characteristics of patients undergoing 
Hybrid ablation 
Clinical Characteristics Continuous variables median (IQR) 
Age (years) 67.5 (60 -70.75) 
Sex 44 M, 10 F 
BMI 30 (27.6 -32) 
Continuous AF Duration leading up to ablation 
(months) 
24 (13.25-35.75) 
Time in AF over previous 10 years (months) 34.5 (24-45.25) 
Number of DCCV 2 (1-2.75) 
CHADS-VaSc Score 2 (1-2) 
Left Atrial AP diameter (mm) 46 (43-49) 
Left Ventricular Ejection Fraction (%) 55 (50-59.75) 
EHRA symptom class 2 (2-2) 
 
3.4.1 First stage surgical ablation 
 
The median procedure duration including anaesthesia was 180 minutes and following ablation, 
epicardial left atrial conduction block was demonstrable in thirty of the fifty-four (55.5%) and 27 of 
the 49 (55%) who have undergone subsequent EPS. Patients were discharged a median of 3 days 
(IQR: 3-4) post operatively and 22 of the 54 (40.7%) were discharged in sinus rhythm after the first 
stage of the procedure.  
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On presentation for the second stage EP study seventeen out of forty-nine patients (35%) were in 
sinus rhythm, eight patients presented in an atypical atrial flutter (16%), one in an atrial tachycardia 
(2%) and the rest were in atrial fibrillation (47%). 
3.4.2 Second stage electrophysiological study 
 
Electrophysiological study was performed in all forty-nine patients without complication. The LA 
posterior wall was isolated at baseline in ten patients (20.5%) and further LA ablation was required 
in thirty-nine (79.6%). Of the twenty-seven patients with confirmed epicardial LA posterior wall 
isolation following surgical ablation, only eight remained isolated at the electrophysiological study 
second stage (29.6%).  LA posterior wall isolation was achieved in all but two patients (4%). A Cavo-
tricuspid isthmus line was completed in all but five patients, due to operational time constraints.  
3.4.3 Gaps in the Epicardial Ablation lines 
 
Gaps in the surgical ‘box’ were identified most commonly along the left superior pulmonary vein, 
roofline and around the right superior pulmonary vein. In our series, there was a median number of 
3 gaps (IQR: 1-4) per patient (figure 3-2). 
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Figure 3-3 Location of gaps in epicardial ablation lines requiring further ablation to 
complete left atrial posterior wall isolation at the second catheter ablation stage. Sites of 
gaps in the epicardial ablation lines that were identified at the electrophysiological second 





Forty-nine patients have undergone both stages. Of them, forty-three are currently more than three 
months after the catheter second stage. At the time of submission, 43 patients have a median 
follow-up of 19 months (IQR: 11.5 - 25) and twenty-seven (62.7%) remain arrhythmia free – twenty-
six (60.4%) off anti arrhythmic drugs. Sixteen patients had a recurrence of an atrial arrhythmia 
outside of the three-month blanking period. At most recent follow-up, thirty-six of the 43 patients 
(83.7%) are in sinus rhythm, thirty-one (72%) off antiarrhythmic drugs. One patient had recurrence 
of AF early in the blanking period after the 2nd stage procedure but refused further rhythm control 
management so is included as a failure in these results. 
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Thirty-two patients are more than 12 months (median 22.5, IQR 17.75 – 32.25 months) post the 
second catheter ablation stage. Of these, nineteen (59.4%) have remained arrhythmia free off 
antiarrhythmic drugs following the three-month blanking period after the catheter second stage. 
Twenty-eight of this group of patients are currently in sinus rhythm (87.5%) and twenty-three of 
these (82%) are off antiarrhythmic drugs. 
Table 3-2 Summary of arrhythmia recurrences 
Recurrences 
Recurrence Rhythm Management Current Rhythm 
AF DC Cardioversion Persistent AF 
Persistent AF 
Persistent AF 
Extensive anterior LA scar Permanent AF 
Refused further rhythm 
management 
Permanent AF 
Early reconnections so further 
LA ablation 
SR off AADs 
Self-reverted SR off AADs 
Chemical CV SR on Amiodarone 
DCCV SR off AADs 
DCCV SR off AADs 
Amiodarone augmented DCCV SR on Amiodarone 
Chemical CV SR off AADs 
Atypical AFL EPS with intact box lesion but 
extensive LA scar 
SR on Amiodarone 
Further LA ablation and PPM 
implantation 
Permanent AF 
EPS + ablation Atypical Flutter 
Right Sided AT RA ablation and PPM 






Left Atrial Posterior Wall isolation for the treatment of Persistent AF Guy Furniss 
 90 
3.4.4.1 Symptom Level 
 
The European Heart Rhythm Association AF symptom score was recorded at each follow-up visit and 




3.4.5.1 Surgical First Stage 
 
Two procedures had to be abandoned due to pericardial adhesions prohibiting pericardial access 
and deployment of the device. Thirteen patients had raised hemi-diaphragm on chest X-ray post-
surgical 1st stage. Of these, seven had complete resolution on chest X-ray and fluoroscopy at the 
electrophysiological 2nd stage; six had continued weakness of right diaphragm with evidence of a 
residual right phrenic nerve praxis. This resolved in all patients within 12 months.  One additional 
patient developed a right-sided haemothorax after flying within one week of the VATS procedure 
and a further patient developed a reactive right sided pleural effusion one month after the 
procedure, both required drainage. One patient with and abnormally high right diaphragm was 
deferred after diaphragmatic injury and was subsequently successfully completed. 
 
One of the first patients enrolled suffered a fatal thromboembolic stroke 24 hours after the surgical 
procedure. He was eating breakfast 18 hours post-operatively when the stroke occurred. Following 
this case our practice changed regarding anticoagulation. A further patient had transient facial 
weakness post-surgery. Signs of cerebral ischaemia were detected on an MRI scan, but a CT Head 
scan was negative for stroke. 
3.4.5.2 2nd Stage Electrophysiological Catheter Study  
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There have been no intra-procedural complications with the catheter 2nd stage. One patient who 
required right atrial ablation for a focal atrial tachycardia was found to have prolonged symptomatic 
sinus pauses after the procedure and required a permanent pacemaker prior to discharge. Another 




3.5 Discussion  
 
This series is of a highly symptomatic group of patients with long-standing persistent atrial 
fibrillation for whom catheter ablation alone has traditionally provided poor long-term outcomes. It 
is more homogenous in this respect than previously published studies of hybrid ablation. The 
heterogeneity of previous hybrid ablation series and difficulty in interpretation of their results has 
been highlighted186,187. The intensity of monitoring during follow-up has also been variable in 
reported series. The outcomes from this series appear superior to the outcomes from catheter 
ablation alone in the treatment of longstanding persistent atrial fibrillation. This could point to a 
more durable lesion set or it may be that the benefit lies in more effective ablation of epicardial 
triggers of AF such as ganglionic plexi. It will not be until robust long-term (5 year) outcome data is 
known that it will be possible to fully evaluate the value of this technique.  
  
The first Cox-Maze surgical technique is now 30 years old and long-term outcomes of this and the 
subsequent Cox-Maze III procedure performed on cardio-pulmonary bypass remain excellent 
184,185183,161,184,185. The development of the Cox-maze IV technique in 2004, incorporated minimally 
invasive thoracoscopic surgical techniques which could be performed without cardio-pulmonary 
bypass. These techniques failed to match the Cox-maze outcomes however and hybrid ablation 
techniques incorporating either simultaneous or staged electrophysiological study174 were 
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developed. Three techniques for hybrid ablation have been reported; the thoracoscopic encircling 
catheter, the bilateral clamp technique and the subxiphoid pericardioscopic procedure. Outcomes 
for persistent and long-standing persistent atrial fibrillation in the bilateral clamp studies is up to 
88.2%189 and 87.7%%190 freedom from AF symptoms off anti-arrhythmic drugs. Because of the 
demanding learning curve in performing this procedure its widespread application has remained 
limited. 
 
Previous studies of the thoracoscopic encircling catheter described above have produced widely 
differing outcomes. In Le Meir’s series of 19 patients, only 7/19 (36.8%) of all AF patients and 4/14 
(28.6%) of persistent AF patients remained arrhythmia free at one year191. In comparison Bisleri et al 
report 40/45 (88.9%) of persistent atrial fibrillation patients free of symptomatic arrhythmia at one 
year.  
 
Published studies of the sub-xiphoid approach have all described convergent procedures. Multi-
centre series in persistent and long-standing persistent patients have reported 52% of patients 
arrhythmia free off anti-arrhythmic drugs and 76% with194. More recently, one year freedom from AF 
of 86% on anti-arrhythmic drugs and 62.2% off has been described195.  
 
All  of the hybrid techniques have a higher complication rate than published series of catheter 
ablation186 but the unilateral VATS approach described above does appear to have a more 
favourable risk factor profile when compared to the bilateral VATS or sub-xiphoid approach. The 
most common complication in this series is phrenic nerve palsy that, although mostly transient, has 
been associated with a symptomatic deterioration in some patients. In response to these findings 
surgical practice was changed to incise the pericardium further from the phrenic nerve, decrease the 
tension on the pericardial stay sutures and irrigate the pericardium with normal saline during 
ablation delivery to reduce thermal injury to the phrenic nerve.  
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There was one fatal stroke early in this series and anticoagulation protocols were changed in 
response to aim for an INR of 2.0 if the patient is on Warfarin or continue any direct oral anti-
coagulation up to 48 hrs prior to surgery. Heparin is administered at the time of ablation (ACT>300 
secs), is not reversed and anticoagulation restarted in the form of the direct oral anti-coagulant 
Dabigatran in all patients on the evening post surgery.   
 
 
It is highly beneficial, for there to be a close working relationship between cardiac surgeons and 
electrophysiologists in both the initial AF heart team discussions and also in monitoring during 
follow-up and outcome data collection. Patients need to be made aware that this is a two-stage 
process with the initial surgical procedure unlikely to be enough to maintain sinus rhythm.  This is 
borne out in our results and it is essential patients are clearly informed of the duration of treatment 
and commitment to the whole process. 
 
As our study and others demonstrate, surgical ablation carries higher risks than catheter ablation. It 
is therefore important that surgical AF ablation and hybrid AF ablation provide better outcomes if 
this technique is to continue to warrant its place in the international guidelines for Atrial Fibrillation 
Management for longstanding persistent atrial fibrillation. 
3.6 Conclusions 
 
The staged hybrid approach described here with left atrial posterior wall isolation and a right atrial 
cavo-tricuspid isthmus line appears to give superior outcomes at one year to published outcomes of 
longstanding persistent atrial fibrillation patients undergoing catheter ablation138,232. Robust long-
term 5 year outcome data is needed along with randomised control trials focusing on comparing 
surgical, hybrid and catheter techniques all aiming for the same lesion set. The question of whether 
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hybrid ablation is superior due to the use of epicardial ablation or solely because of a two-stage 
ablation process also needs to be addressed.   
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4 Chapter 4 - The effect of atrial fibrillation ablation techniques on P 
wave duration and P wave dispersion 
4.1 Abstract 
 
Background: A reduction in surface ECG P wave duration dispersion is associated with improved 
outcomes in atrial fibrillation ablation. We investigated the effects of different ablation strategies on 
P wave duration and dispersion, hypothesising that extensive LA ablation with left atrial posterior 
wall isolation would give a greater reduction in P wave duration than more limited ablation 
techniques. 
Methods: A retrospective analysis of ECG’s from patients who have undergone AF ablation was 
performed and pre-procedural sinus rhythm ECG’s were compared with the post procedure ECG’s. 
Maximal P wave duration was measured in leads I or II, minimum P wave duration in any lead and 
values were calculated for P wave duration and dispersion. Left atrial dimensions and medications at 
the time of ECG were documented. Ablation strategies compared were; pulmonary vein isolation 
(PVI) for paroxysmal atrial fibrillation (PAF) and the persistent AF (PsAF) ablation strategies of 
pulmonary vein isolation plus additional linear lesions (Lines), left atrial posterior wall isolation via 
catheter (PWI) and left atrial posterior wall isolation via staged surgical and catheter ablation 
(hybrid).  
Results: Sixty-nine patients’ ECG’s were analysed: 19 PVI, 21 Lines, 14 PWI, 15 Hybrid. Little 
correlation was seen between pre-procedure left atrial size and P wave duration (r = 0.24) but LA 
size and P wave duration was larger in PsAF patients. A significant difference was seen in P wave 
reduction driven by Hybrid AF ablation (P < 0.005) and Lines (<0.02). There was no difference 
amongst P wave dispersion between groups but the largest reduction was seen in the hybrid 
ablation group. 
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Conclusion: P wave duration increased with duration of continuous atrial fibrillation. Hybrid AF 
ablation significantly reduced P wave duration and dispersion compared to other ablation strategies 
including posterior wall isolation via catheter despite this being the same lesion set.  
  







Prolonged P wave duration on a standard surface ECG has been associated with the development of 
atrial fibrillation 234235236 and AF recurrence following catheter or hybrid ablation. Conversely a 
reduction of P wave duration has been associated with favourable outcomes following ablation of 
atrial fibrillation 237238239 
 
P wave dispersion is the difference between the longest and shortest P wave duration on a surface 
ECG240241242 and prolongation is associated with atrial fibrillation development in coronary artery 
disease and post cardiothoracic surgery243244 as well as a number of other clinical situations242. 
Reductions in P wave dispersion are associated with favourable outcomes following AF ablation245.  
 
The cause of P wave prolongation is complex but intra atrial conduction delay or block due to 
structural, neurohormonal or autonomic mechanisms have been implicated242 while shortening of 
the P wave duration and P wave dispersion following AF ablation has been proposed to be due to 
structural atrial changes 246. 
 
International guidelines recommend ablation for drug refractory AF and a wide range of approaches 
exist247. Improved outcomes are associated with P wave shortening for both paroxysmal and 
persistent AF in a variety of lesion sets237248249. Pulmonary vein isolation (PVI) is the established 
lesion set for paroxysmal AF but the optimal ablation strategy for persistent atrial fibrillation 
ablation is undefined250. The STAR AF 2 trial showed that the addition of linear ablation or the 
targeting of complex fractionated atrial electrograms provided no increased survival from AF than 
PVI alone138.  An alternative approach is the “box lesion pattern”, involving complete isolation of the 
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pulmonary veins and posterior wall of the left atrium, done via catheter or surgical ablation which 
has shown promise in the treatment of persistent atrial fibrillation although randomised data is 
lacking 196209187161.  
4.3 Aims 
 
In this retrospective study P wave duration on the surface ECG was compared pre and post ablation 
in paroxysmal atrial fibrillation patients following pulmonary vein isolation and persistent atrial 
fibrillation patients who have undergone either catheter ablation or a combined surgical and hybrid 
ablation. The hypothesis is that more extensive ablation will result in greater change in P wave 
duration and dispersion. It would then follow that left atrial posterior wall isolation would be 
associated with the greatest shortening of P wave duration and P wave dispersion due to greater 
atrial structural and substrate modulation than more limited lesion sets.  
4.4 Methods 
 
This was a retrospective study of patients undergoing atrial fibrillation ablation at Derriford Hospital, 
Plymouth from 2012-2016.  Four different ablation approaches were compared: 
 
1. Pulmonary vein isolation (PVI) 
 
This is the standard lesion set for patients with symptomatic paroxysmal atrial fibrillation. Cases in 
this study were performed by two different operators via radio-frequency ablation with contact-
force catheters using either the CARTO (Biosense-Webster, Diamond Bar, California, USA) or Velocity 
(St Jude Medical, St. Paul, Minnesota, USA) systems. 
 
2. Pulmonary vein isolation with additional linear ablation, roof and/or mitral isthmus lines 
but without left atrial posterior wall isolation (Lines) 
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This lesion set was used for patients with symptomatic persistent atrial fibrillation. In these twenty-
one cases the lesion set was created with radio-frequency ablation using CARTO (Biosense-Webster, 
Diamond Bar, California, USA) with contact-force sensing catheters in nine patients and phased array 
PVAC and TVAC catheters (Medtronic, Minneapolis, Minnesota, USA) in twelve cases.  
 
3. Left atrial posterior wall isolation via catheter with PVI + roof and floor lines (PWI) 
 
This lesion pattern was used for later patients with symptomatic persistent atrial fibrillation using 
either the CARTO or Velocity (St Jude Medical, St. Paul, Minnesota, USA) systems with Smart-touch 
(Biosense – Webster, Diamond Bar, California, USA) or Tacticath  (St Jude Medical, St. Paul, 
Minnesota, USA) catheters and contact force availability.  
 
4. Two-stage non-concomitant hybrid ablation (Hybrid) 
  
This procedure is offered to patients with long-standing persistent atrial fibrillation (continuous AF 
duration of greater than one year). It involves a surgical epicardial stage to isolate the left atrial 
posterior wall and target ganglionic plexi using the Cobra Fusion device (Atricure Inc, Minneapolis, 
US) with a later catheter ablation stage to confirm and re-isolate the left atrial posterior wall if 
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Figure 4-1 Creation of the lesion sets in the study. Panel A shows the PVAC catheter on the 
left and TVAC catheter on the right. This was used in 12/21 cases to isolate the pulmonary 
veins and perform linear ablation. Panel B shows the final lesion set following left atrial 
posterior wall isolation via catheter ablation using the Velocity system. Panel C 
demonstrates the two stage hybrid ablation process whereby on the left the left atrial 
posterior wall is isolated first by epicardial ablation using the Cobra Fusion device. 
Patients then return for electroanatomical mapping and further ablation to complete 
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As this study was a retrospective observational study of anonymised ECG’s formal ethical approval 
was considered to be unnecessary and was not sought.  
 
Patients were identified from local registries of ablation procedures from two different operators. 
Hospital notes were then searched for twelve-lead ECG’s in sinus rhythm prior to the ablation 
procedure and ECG’s taken immediately after the procedure. Where multiple ECG’s were available 
those closest to the ablation procedure were used. If the patient was in atrial fibrillation at the time 
of ablation the most recent ECG in sinus rhythm prior to the ablation was used. Details of left atrial 
dimensions and antiarrhythmic medication were documented at the time of the ablation procedures 
and recorded from the notes. 
 
Measurement of maximal P wave duration on the ECGs was taken from the limb leads II or I using 
callipers and a rate ruler. All the ECGs used had been recorded at standard ECG settings of 25mm/s 
and 10mm/mV. One investigator identified and selected the ECGs as well as making the initial 
measurements of maximal P wave duration. The ECGs were then anonymised and randomised 
before being re-measured by three further investigators blinded to the initial results, ablation 
approach and timing of the ECG. At this stage an additional measurement of the minimal P wave 
duration in any lead was calculated in the anonymised ECGs and a measurement of P wave 
dispersion was made by subtracting the largest P wave in the limb leads (I or II) from the shortest P 
wave duration in any lead. This resulted in four measurements of maximal P wave duration and 
three measurements of P wave dispersion for each ECG. The change in P wave duration and P wave 
dispersion pre and post ablation was calculated for each procedure and a mean value calculated for 
each procedure.  
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Figure 4-2 Reduction in P wave duration seen on a surface ECG pre and post AF ablation 
(Lead II, 25mm/s, 10mmm/1mV) 
 
 
The P wave duration, P wave reduction post ablation and the P wave dispersion measurements were 
compared for each ablation approach.  
 
4.4.1 Statistical Analysis 
 
Values given are mean (+/- standard deviation) unless stated otherwise. Change in P wave 
was compared between pre ablation and on the first ECG post procedure for each group 
with the Kruskal Wallis test used to analyze variance between groups and a using Wilcoxon 
Signed Rank Test used to compare interventions as the data was not normally distributed 
(Shapiro-Wilks test on change in P wave duration p=0.07). Correlations between P wave 
change and left atrial AP diameter were examined using the Spearman correlation. 









Eighty-five procedures were identified from the registries of the different AF ablation approaches; of 
these only sixty-nine patients had usable ECG’s available from before and after the procedure. This 
resulted in nineteen in the PVI group, twenty-one in the Lines group, fourteen in the PWI and fifteen 
in the hybrid group. The patients who underwent PVI were all paroxysmal atrial fibrillation patients, 
whereas those in the Lines, PWI, and hybrid groups all had persistent atrial fibrillation. All of the 
Hybrid group had longstanding persistent atrial fibrillation with continuous atrial fibrillation 
durations or greater than one year.   
 
The increasing duration of atrial fibrillation was reflected in an increasing left atrial size between 
groups from PVI to Hybrid and also an increasing initial P wave duration from PVI to hybrid. There 
was little correlation between P wave duration and left atrial AP diameter (r = 0.2475). No difference 
was seen in medications between ECG recordings as patients had antiarrhythmic medications 
continued up until the ablation procedure and were taking these drugs when the post-ablation ECG’s 
were recorded on the day of procedure. 
 
The findings of left atrial AP diameter, P wave change and P wave dispersion can be seen in Table 1.  
 















































PVI 19 Paroxysmal 
AF 
36.79 114 58.5 0.66 5 (-7.1-
14.2) 




Lines 21 Persistent AF 42.25 123 64 -10.51 -10.51 (-
25- 2.5) 
p <0.02 -7.71 -10 (-20 - 
10) 
p=0.17 
PWI 14 Persistent AF 39.64 118 51 -7.86 0 (-21.7 
- 0) 
p = 0.21 -6.86 0 (-33 - -
6.9) 
p=0.57 
Hybrid 15 Longstanding 
Persistent AF 
46.2 133 69 -27.45 -37.5 (-
50 - -
3.75) 





Left Atrial Posterior Wall isolation for the treatment of Persistent AF Guy Furniss 
 104 
 
4.5.1 Intra-observer variability 
 
One-hundred and twelve measurements of maximal P wave duration were recorded by all four 
observers. As minimal P wave duration was measured only by the three blinded observers they 
made a further 154 measurements on the study ECG’s.  The intraclass coefficient (ICC) statistic for 
the four observers was 0.58 (95% CI: 0.46-0.67) and when the same lead was used by each observer 
the reliability improved with an ICC statistic of 0.63(95% CI:0.5-0.74).  
 
Correlation between the blinded measurements was excellent. Two-hundred-and-seventy-six 
measurements of maximal or minimal P wave duration were made by each of the three observers 
with a calculated ICC statistic of 0.8 (95% CI: 0.72-0.86).  
4.5.2 P wave duration 
 
A significant difference was seen in the change in mean P wave duration between groups (Kruskal-
Wallis rank sum test p = 0.016).  Hybrid ablation produced the largest reduction in P wave duration, 
followed by the Lines group, PWI and then PVI. There was a trend towards statistical significance 
comparing the Hybrid group against Lines (p=0.076) and PWI (p = 0.06) but significance was only met 
compared to PVI alone. (p= 0.005). The Lines group had the next most significant reduction in P 
wave duration and this was again statistically significant against the PVI group (p=0.04) but not 
against PWI (p= 0.35).  (Fig 2) 
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4.5.3 P wave dispersion 
 
The Kruskal-Wallis test did not suggest a significant difference between groups (p= 0.44) but again 
there was a greater reduction in mean P wave dispersion with complexity of ablation from PVI to 
Hybrid ablation, which resulted in the largest decrease in P wave dispersion. The Hybrid group was 
the only approach to achieve a statistically significant difference when compared against the 
combined other three approaches (p = 0.02).  
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In this study the association between different ablation strategies and changes in surface ECG P 
wave duration and P wave dispersion following ablation was investigated. The hypothesis was that 
more extensive ablation would lead to greater change in P wave duration. These simple 
measurements have been shown to be easily measured on a standard 12 lead ECG240 and 
prolongation of both has previously been shown to be associated with the development of atrial 
fibrillation236 234 while reductions of P wave duration and dispersion following catheter ablation 
confers better outcomes245251252.  
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This study demonstrates that measurements of P wave duration on standard ECG’s can be reliably 
and reproducibly analysed. There was fair to good correlation between all four observers, which was 
improved when the same ECG lead was used. Correlation amongst the three observers who made 
blinded measurements was excellent. Given that standard ECG’s were measured with the need to 
round measurements up or down to the nearest 10ms it is to be expected that some intra observer 
variability was seen. For further study it may be that measuring ECG’s at 50mm/s rather than the 
standard 25mm/s would improve accuracy and even result in improved correlation.  
 
As in previous studies238, P wave duration in this study was associated with the duration of atrial 
fibrillation and increased from patients with paroxysmal atrial fibrillation to patients with persistent 
and longstanding persistent atrial fibrillation.  Left atrial size also increased between these groups 
but no correlation was seen between the left atrial AP diameter and P wave duration suggesting 
structural changes alone do not account for p wave prolongation.  
 
The largest reduction in surface ECG P wave duration following ablation was seen in the Hybrid 
ablation group but a significant reduction was also demonstrated in the group who underwent 
pulmonary vein isolation with linear ablation (roof and mitral isthmus ablation). Hybrid ablation 
alone resulted in a significant reduction in P wave dispersion when compared to the other ablation 
approaches. This supports the findings from previous studies that reductions in P wave duration and 
P wave dispersion are seen following AF ablation but the study was not designed to obtain follow-up 
to provide outcome data in these groups.  
 
The mechanism determining P wave duration is not known but is most likely due to a complex series 
of factors including structural changes in the atrium, atrial fibrosis, intra –atrial conduction time and 
autonomic innervation24,72,52. The findings of this study would suggest that more extensive ablation is 
linked with greater reduction in P wave duration but the confounding factor is that P wave duration 
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increases with duration of atrial fibrillation and longer durations of atrial fibrillation have more 
complex ablation strategies.   
 
The greatest change in P wave duration and P wave dispersion was seen in the Hybrid group. The left 
atrial posterior wall isolation lesion set in the Hybrid and PWI groups was identical and the main 
difference between them is the surgical epicardial ablation and ganglionic plexi excision in the 
Hybrid group. although greater lesion durability and a more intact “box” lesion pattern could be 
inferred from chapters 2 and 3.  
 
One claimed advantage of surgical ablation over catheter ablation is that ganglionic plexi can be 
directly targeted and excised which may result in greater autonomic modulation154. In this study P 
wave duration was longer in the Hybrid group at baseline but greater reductions in P wave duration 
and P wave dispersion were seen in this group compared to the PWI group.  No measurement of 
autonomic modulation was made in these cases but autonomic triggers for atrial fibrillation are well 
described. Studies have shown that targeting ganglionic plexi, which can be mapped endocardially 
and targeted by catheter ablation can improve outcomes of atrial fibrillation ablation25,32,54,148. 
Changes in autonomic innervation have also been shown to effect the P wave on a surface ECG 256 
while P wave prolongation has been demonstrated in spinal injury patients with autonomic 
dysfunction who had a subsequent increased risk of AF257 and also diabetics with neuropathies258.  
 
The association between epicardial ablation, ganglionic plexi excision and changes in P wave 
duration and P wave dispersion warrants further study. If these are surrogate markers of autonomic 
modulation then it may be that where P wave duration or dispersion is shortened by catheter 
ablation from any approach it is due to ablation of autonomic triggers rather atrial substrate 
modulation. This could provide a novel measurement to assess the degree of autonomic modulation 
following a catheter or surgical ablation as well as give an indication of the likelihood of AF 
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recurrence. Further research could lead to alternative ablation end-points or follow-up strategies for 
patients whose P wave duration remains prolonged. 
4.6.1 Limitations of the study 
 
This is a small retrospective observational study in which baseline P wave duration varied between 
groups. Longer pre-ablation P wave duration may allow for greater P wave shortening with ablation. 
I have not made a direct randomised comparison between ablation techniques and the mean post 
procedure P wave duration is similar across all groups. There is a greater change in P wave 
dispersion with a lower post procedure value after hybrid ablation than seen in other groups but this 
is again non-randomised data that may be susceptible to unrecognised confounding factors.    
 
The ECG measurement of P waves was limited by the retrospective study design in which only 
standard ECG’s were available. Greater accuracy may be shown by either using ECG’s at 50mm/s 
speed or automated measurement. It may also have been possible to enlarge the ECG’s for 
measurement. Due to the use of standard ECG’s the measurement of P wave duration was always to 




P wave duration and P wave dispersion increased with duration of continuous atrial fibrillation from 
paroxysmal to long-standing persistent atrial fibrillation. Hybrid AF ablation was associated with the 
largest reduction in P wave duration post ablation and was the only technique associated with a 
significant decrease in P wave dispersion.  We hypothesise that the greater reduction in P wave 
dispersion is due to autonomic rather than substrate modulation. 
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5 Chapter 5 – Minimally invasive assessment of posterior wall 




Background: Left atrial posterior wall isolation (LAPWI) via catheter, surgical and hybrid techniques 
is a promising treatment for persistent atrial fibrillation (PersAF). We investigated whether 
confirmation of LAPWI can be achieved using an oesophageal pacing and recording electrode.  
Methods: Patients undergoing PersAF ablation with the intention to achieve LAPWI were enrolled. 
Two approaches to LAPWI were tested: 1) ablation using endocardial catheter ablation only, 2) 
‘Staged Hybrid’ ablation with thoracoscopic epicardial ablation, followed by endocardial left atrial 
electrophysiological study and catheter ablation where necessary. Patients enrolled in the study all 
required further catheter ablation to achieve LAPWI in this group. 
In both groups, oesophageal recording and oesophageal pacing was performed at the start of 
mapping and electrophysiological study and compared with endocardial electrophysiological 
findings.  This was repeated at the end of the procedure.  
Results: Twenty patients (16M, 4F) were studied. Endocardial electrophysiological study showed 
that in none of the cases was the posterior left atrial wall electrically isolated at the start of the 
study. One patient with Barretts oesophagus failed to sense or pace from the oesophagus at any 
point in the study. In the remaining 19/19 oesophageal pacing captured the atrial rhythm at the start 
of the procedure. LAPWI was then achieved in 17/19 using endocardial catheter ablation; retesting 
at this point showed sensing and capture of the atrium from the oesophagus was abolished. In the 
remainder sensing and capture persisted. 
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Conclusions: Oesophageal pacing can be used to confirm or refute electrical isolation of the left 
atrial posterior wall. 
  




The optimal ablative treatment of persistent atrial fibrillation is unclear and outcomes lag behind 
those achieved in treating paroxysmal atrial fibrillation138,231,259. This has led to the use of lesion sets 
such as left atrial posterior wall isolation (LAPWI - the ‘box’ lesion pattern) based on the modified 
Cox-Maze surgical technique260 created via catheter, surgery or hybrid approaches. Series in 
persistent and long-standing atrial fibrillation have shown promising results207,216,261,262. (figure 5.1) 
 
Guidelines published in 2016 have given a class IIa recommendation for thoracoscopic approaches 
utilising the left atrial posterior wall isolation lesion set229 for persistent atrial fibrillation.  
Published studies of two-staged hybrid ablation approaches for AF give varying outcomes from the 
surgical first stage. The requirement for further ablation to complete the left atrial posterior wall 
lesion set at the electrophysiological second stage varies significantly from 72%263 of procedures to 
as few as 20% 264. In all series a significant number of patients undergo an unnecessary second stage 
electrophysiological study.  
5.2.1 Rationale for the study 
 
The oesophagus lies directly behind the heart and is in contact with the left atrium265. It has long 
been known that the heart can be paced through the oesophagus in emergencies266,267,268 and all 
ablating electrophysiologists are aware of the dangers of oesophageal trauma with left atrial 
ablation. CT studies have shown that the oesophagus is in contact with the left atrium throughout 
the cardiac cycle269. It may run a course closer to the right or left pulmonary veins265,270, but it always 
contacts the posterior left atrium. 
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Oesophageal temperature probes can be used during left atrial ablation although questions have 
been raised about the benefit of routine use271,272. They can also be used as a stable reference for 3D 
mapping systems during the electrophysiological study266–268 and some will pace the left atrium. 
 
Figure 5-1 Left atrial posterior wall isolation (including the pulmonary veins) via catheter 
(panel A) and following the second stage of the hybrid ablation with lesions delivered to 
the roof line to achieve isolation (panel B) 
 
5.3 Aims  
 
In this feasibility study, we sought to establish whether oesophageal pacing catheters could confirm 
or refute left atrial posterior wall isolation with entrance and exit block following ablation compared 
to the ‘gold standard’ of concurrent intracardiac electrophysiological study.  
 
We aimed to develop a technique that could be of value by potentially allowing verification of the 
persistence of LAPWI remote from the time of ablation and be of clinical value in staged hybrid AF 
ablation procedures, identifying those patients who have had the left atrial posterior wall isolated 
and require no further left atrial ablation. These patients could be saved an unnecessary atrial trans-
septal puncture and left atrial study, avoiding exposure to risks that potentially include stroke, 
tamponade and fatality.    
 





Participants were recruited from patients referred to the electrophysiological service at The South 
West Cardiothoracic Centre, Derriford Hospital, Plymouth, UK. Full ethical approval was granted by 
the Devon and Cornwall Research Ethics Committee prior to recruitment and all patients gave 
written informed consent.   
 
All participants in this study were undergoing ablation for drug-refractory, symptomatic, persistent 
atrial fibrillation. Multi-disciplinary team and patient discussion determined which patients received 
the staged ‘Hybrid’ approach and which patients received catheter ablation only.   
 
5.4.1 Methodology of the ablation approaches 
 
5.4.1.1 Staged Hybrid Approach (Figure 2) 
 
5.4.1.1.1 The Surgical 1st Stage 
 
The technique for surgical AF ablation utilised the Cobra Fusion Device (Atricure Inc. Minneapolis, 
USA) through a right-sided VATS under general anaesthetic. This is described in detail in chapter 3. 
5.4.1.1.2 Endocardial Electrophysiological 2nd Stage 
 
The second stage procedure is performed a minimum of 8 weeks after epicardial surgical ablation to 
allow time for conduction to recover at any non-permanent sections of the surgical ablation line. The 
study is performed under a general anaesthetic via vascular access from the right femoral ± right 
subclavian/internal jugular veins. It is described in Chapter 2 and 3. 
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5.4.1.1.3 Oesophageal instrumentation: 
 
An oesophageal pacing and recording electrode (‘Box Check’ Oesophageal Catheter, Dot Medical Ltd, 
UK) is passed via the oropharynx (usually nasally) after induction of anaesthesia and the position of 
the recording and pacing electrodes adjusted to lie as centrally as possible in the area of the left 
atrial posterior wall using fluoroscopy (Figure 5-2). 
5.4.1.1.4 Endocardial instrumentation: 
 
Atrial trans-septal puncture is performed under fluoroscopic guidance using standard orthogonal 
views and unfractionated heparin is given to maintain an activated coagulation time of greater than 
300s. SL1 and Agilis sheaths (St Jude Medical, St. Paul, Minnesota, USA) are passed through the same 
aperture in the interatrial septum to give access to the left atrial chamber. If the patient is in atrial 
fibrillation a cardioversion to sinus rhythm was performed.  
 
At this stage in the procedure, the oesophageal pacing and recording study was performed. It was 
then repeated once LAPWI had been confirmed by endocardial electrophysiological study at the end 
of the procedure. (Procedural methodology is described in in chapter 2) 
5.4.1.2 Catheter Ablation Only approach 
 
All catheter ablation only patients underwent radio-frequency ablation under general anaesthesia. 
The same oesophageal pacing and recording method was used as in the Hybrid patients described 
above. The methodology of this technique has been extensively described in chapter 2. 
 
Left Atrial Posterior Wall isolation for the treatment of Persistent AF Guy Furniss 
 116 
The goal at the end of both approaches was to achieve left atrial posterior wall isolation, confirmed 
by entrance and exit block into and out of the left atrial posterior wall and by demonstration of 
pacing and capture within the isolated area without conduction to the rest of the atria.   
 
The oesophageal pacing and recording procedure was performed again at this stage (detailed 
methodology described below under ‘Oesophageal study during electrophysiological study/catheter 
ablation’). 
 
Post procedure, all patients are prescribed one month of proton-pump inhibitors as part of the 
oesophageal protection protocol post both the catheter only and 2nd stage hybrid ablation 
procedures.  
5.4.1.3 Oesophageal study during electrophysiological study/catheter ablation 
 
Following induction of general anaesthesia, the quadripolar oesophageal electrode (Box Check 
Catheter, Dot Medical, UK) is passed to an initial 40cm depth via the oropharynx  (nasally in 15 of the 
20 cases) and screened using fluoroscopy to confirm placement behind the left atrium. The position 
is adjusted by withdrawing or advancing the catheter until the 2 central electrodes used for pacing 
and recording are level with the central area of the left atrial image on fluoroscopy (Figure 4). The 
oesophageal catheter is visible on the 3D mapping system (Velocity/Precision St Jude Medical St. 
Paul, Minnesota, USA) and the position of the initial baseline pacing study is stored. Fluoroscopically, 
the intervertebral discs and their relation to the two central electrodes used for the pacing and 
recording is noted. These parameters allow a reference for repeat study following ablation. 
 
As described above, patients in atrial fibrillation following introduction of catheters into the left 
atrium are cardioverted before EPS is undertaken. 
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Electrogram sensing and pacing is performed using the middle poles (2,3) and analysed and 
programmed through the BARD workstation (Boston Scientific, Marlborough, Massachusetts, USA).  
 
Recordings were made of the oesophageal electrograms at the start and end of the left atrial 
electrophysiological study (EPS) and ablation (figure 5-2). Pacing was performed on the 2 central 
electrodes of the oesophageal catheter starting at 5mA and increasing incrementally up to 25mA at 
a rate above the sinus rate until either capture of the atrial rhythm was observed, or 25mA was 
reached without capture. 
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Figure 5-2 Oesophageal pacing during catheter ablation. Panel A shows placement of the 
catheter behind the left atrium just after trans-septal puncture. Panel B shows the end of 
a case with a circular A-Focus II intracardiac catheter in the left atrium. Panel C shows 
atrial sensing on the oesophageal channel (OP 1-2, 2-3, 3-4). Panels D and E show the 
difference pre and post left atrial posterior wall isolation. Sensing is seen in Panel D and 
failure to capture in Panel E. 
  





Twenty patients (4 females, 16 males) were studied, 9 had previously undergone the first (surgical) 
stage of the staged Hybrid ablation approach and 11 underwent catheter ablation only.  In two of 
the catheter ablation patients a clinical decision was made after starting the case not to isolate the 
left atrial posterior wall, one patient receiving pulmonary vein isolation only and the other a roof 
and mitral isthmus line only. In these 2 cases we were able to confirm sensing and pacing via the 
oesophageal catheter at the start of the case and oesophageal study at the end of the case 
demonstrated ongoing sensing and pacing capture of the left atrium from the oesophagus. 
5.5.1 Oesophageal study during electrophysiological study/ablation 
 
In all patients studied, the left atrial posterior wall was not isolated at the start of the procedure. In 
chapter 3 a relatively low rate of LAPWI as a result of the first stage of the hybrid ablation approach 
was observed. Of the nine patients who underwent hybrid ablation, four had confirmed left atrial 
posterior wall exit block following epicardial ablation. However, the posterior wall was not isolated 
in any case at the start of the electrophysiological study.  To complete the lesion set a median of two 
gaps in the ablation lines needed completion.  
 
In nineteen out of all twenty cases (95%) we were able to pace and sense the left atrium from the 
oesophageal catheter at the start of the case. The one patient we were unable to pace or sense from 
the oesophagus was a patient with known Barrett’s oesophagus who had previously undergone 
several gastroscopies, demonstrating scarring and fibrosis in the oesophagus. Failure to capture the 
atrial rhythm at 25mA was observed in this case despite intracardiac electrograms and pacing 
showing that the left atrium had not been isolated. 
 
Left Atrial Posterior Wall isolation for the treatment of Persistent AF Guy Furniss 
 120 
Excluding the patient that we were unable to study and the two patients who did not undergo left 
atrial posterior wall isolation left seventeen patients.  In these we could directly compare the left 
atrial study with the oesophageal findings before and after LAPWI. All demonstrated clear 
oesophageal atrial electrograms and capture of the atrial rhythm with oesophageal pacing at the 
start of the procedure with electrical silence or small ‘blunt’ electrograms on the oesophageal 
catheter following ablation and no capture of the left atrium at 25mA@10ms once left atrial 
posterior wall isolation had been achieved (Table 5-1).  
 
In figure 5-3 panel A the oesophageal pacing impulses can be clearly seen on all channels however 
despite adjusting the filtering significant artefact was generated across the atrial and coronary sinus 
electrodes. It is still possible to see atrial electrograms in the coronary sinus and right atrium 
following the oesophageal impulses. To highlight this in figure 5-3 the oesophageal pacing impulses 
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Table 5-1 Summary of Oesophageal pacing during EPS 
 
Summary of Oesophageal pacing during EPS findings 
 
Key - LA – Left Atrium, OP – oesophageal pacing, PW – left atrial posterior wall, EPS block – invasive entrance and exit block, OP PW block 
– oesophageal entrance and exit block. 
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Figure 5-3 Panel A - Oesophageal pacing at the start of a case with pacing stimuli 
illustrated by the blue arrows and atrial capture seen on the coronary sinus catheter (red 
arrows). Panel B - oesophageal pacing failing to capture the left atrium following left atrial 
posterior wall isolation. Atrial activity is independent of the paced rate. (Pacing stimuli – 
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If we include all patients in our analysis, including the one with Barrett’s oesophagus, 
electrophysiology study of all twenty patients studied showed that the left atrial posterior wall was 
not isolated at baseline. Of those, eighteen patients who underwent successful left atrial posterior 
wall isolation following catheter ablation we were unable to pace the atrium in any case. Overall the 
catheter was compared to invasive electrophysiological study forty times (before and after ablation). 
As a test for left atrial posterior wall isolation where a positive finding was being unable to pace from 
the oesophagus we had one false positive (being unable to pace the atrium where the LAPW was not 
isolated) and no false negative results (being able to pace the atrium despite the EPS showing LAPW 
isolation). This small study gives a positive predictive value of 94.44% (CI 75- 99.98%), sensitivity of 
100% (CI 80.49 – 100%) and a specificity of 95% (CI 75.13 – 99.87%). The negative predictive value in 
this study was 100%. 
5.5.2 Complications 
 
The single complication during the study was a short episode of epistaxis occurring during a catheter 
ablation case. No patients complained of any residual effects of study.  
5.6 Discussion 
 
Oesophageal pacing catheters are rarely used outside of paediatric populations for emergency 
purposes273. Use in adults is unnecessary for treatment of bradycardia due to the ease of alternative 
methods of temporary pacing.  Likewise the historic use of oesophageal catheters for study of supra-
ventricular tachycardias in adults274 has been superseded by invasive electrophysiology. Yet recently 
oesophageal electrophysiological study has made a comeback with catheters used for ambulatory 
monitoring and investigation of atrial fibrillation275. These give superior visualisation of atrial activity 
compared to surface ECG P waves 276 and these studies highlight the tolerability and ease of use of 
the oesophageal catheters in outpatient settings.  
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Left atrial posterior wall isolation, the “box lesion pattern”, is a lesion-set based on the Cox-Maze 
surgical procedure and can be created via catheter, surgical and hybrid atrial fibrillation ablation. 
Outcomes from series of both catheter ablation 207 and surgical ablation 277,278 are generally better 
when pulmonary vein isolation (PVI) plus left atrial posterior wall isolation is compared with 
pulmonary vein isolation plus only a single roof or floor line. This type of lesion set where ablation 
lines were added to PVI without ‘closing the box’ were studied in the STAR AF II trial (pulmonary vein 
isolation plus roof and mitral isthmus linear ablation or CFAE ablation) and yielded poor results 138. 
Although a meta-analysis of catheter ablation studies of left atrial posterior wall isolation supported 
the value of the technique 261, one randomised study comparing PVI plus ‘open’ or ‘closed’ box 
approaches showed no benefit from posterior wall isolation 206. Data is accumulating supporting the 
value of the ‘box’ lesion set 216,263 with guidelines supporting left atrial posterior wall isolation with a 
IIb recommendation121. However randomised data is limited 207 and further research clearly needed.  
 
In this study, we set out to develop a technique of detecting the presence or absence of left atrial 
posterior wall isolation (‘box set lesion pattern’) from the oesophagus using oesophageal pacing 
catheters. The results show that it is feasible to use the oesophagus to verify isolation.  We have 
given the positive predictive value based on our results but, as this is an unblinded small feasibility 
study with only one false positive and no false negatives, further research is required. A larger study 
is required to determine true positive and negative predictive values of this technique and should 
necessarily involve oesophageal study blinded to the results of the intracardiac electrophysiological 
study. 
 
In this study the technique proved to be safe and well tolerated. It was also accurate with initial 
findings on the oesophageal catheter matching the invasive findings in nineteen out of twenty (95%) 
consecutive patients who underwent simultaneous study. In patients where LAPWI was achieved at 
the end of the study, the intracardiac findings agreed with the oesophageal findings in all cases.  The 
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one patient where the technique failed had known Barrett’s oesophagus and repeated gastroscopy 
and biopsy had shown microscopic and macroscopic scarring. We would suggest that Barrett’s 
oesophagus or an alternative condition where fibrosis may be present such as oesophageal 
strictures should be a contra-indication to oesophageal pacing as a means of electrophysiological 
study.  
 
Sra et al have shown that the oesophagus is in contact with the posterior left atrium throughout the 
cardiac cycle269 but may run towards either the left or right pulmonary veins. In every case of our 
study the oesophageal position allowed study of the left atrium with no patient excluded due to the 
course of the oesophagus. Larger studies will be required to confirm our findings, but it does appear 
that the position of the oesophagus does not limit this technique. 
 
Oesophageal pacing potentially offers a quick and safe method of checking the results of a previous 
ablation. In the hybrid ablation population, where the surgical lesion set involves a single ablation 
ring incorporating the pulmonary veins, trans-septal puncture and invasive left atrial study may 
become unnecessary if entrance and exit block from the oesophagus are observed. This could 
reduce the risk of complications such as tamponade and stroke to the patient, while confirming that 
the intended lesion set has been achieved. Thus, selected patients undergoing hybrid AF ablation 
could potentially be studied as out-patients following the surgical first stage and this could also be 
incorporated into standard follow-up of surgical AF ablation where the intention is to isolate the left 
atrial posterior wall. We propose a short procedure requiring fluoroscopy and a system analyser for 
the oesophageal electrode.  A method exists to predict the level of the left atrium for oesophageal 
pacing using patient height 279 but a few seconds of fluoroscopy adds a greater accuracy to the 
procedure at minimal additional risk. Further study could increase the accuracy of using the 
oesophageal catheters “blind” but we would currently recommend fluoroscopy in all cases.  
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5.6.1 Limitations of the Study 
 
This is a small feasibility study of a novel technique. Larger studies may reveal more limitations. The 
finding that the technique did not work in a patient with significant oesophageal pathology raises 
the question whether some patients who may have undetected oesophageal abnormalities could 
produce misleading results, but this situation is likely to be rare. We also found the position of the 
oesophagus allowed left atrial study in all cases however this may not be the case in larger studies.  
 
Significant artefact was seen during oesophageal pacing which is demonstrated in figure 5-3. We 
adjusted the filtering in the atrial and CS channels to minimise this, but it was present in all cases. 
Despite this the electrical artefact did not limit the technique. Further study may highlight greater 
issues with artefact that limits the utility of oesophageal pacing. However it will also allow 
refinement of the procedural setup to limit this phenomenon.   
 
In most cases of catheter ablation where LAPWI is achieved, the pulmonary veins are isolated first by 
wide area circumferential ablation (WACA) followed by performing roof and floor lines. The 
oesophageal pacing technique appears accurate in determining whether the area of the left atrial 
posterior wall between the roof and floor lines and the posterior (WACA) lines is isolated. However, 
reconnection across the anterior aspect of the WACA would not be detected if the posterior part of 
the encircling lesion between the points of connection to the roof and floor lines remained intact. 
Thus, it would be possible for a patient to have LAPWI verified by oesophageal study, but have 
reconnection of a pulmonary vein pair via a break in the anterior WACA line. This possibility would 
not occur if endocardial linear catheter ablation tools become available which would isolate the 
whole posterior wall and pulmonary veins as a single ‘box’ lesion set similar to the surgical 
approaches.   




Oesophageal pacing catheters can be used to check left atrial posterior wall isolation following atrial 
fibrillation ablation. Routine use as part of surgical and hybrid atrial fibrillation ablation programmes 
could allow checking of left atrial posterior wall ablation results without the need for invasive 
electrophysiological study and its attendant risks. It could also be used for routine follow-up or 
research study of patients who have undergone catheter, hybrid or surgical AF ablation where the 
intention has been to electrically isolate the posterior wall of the left atrium.  
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6 Chapter 6 - Development of an outpatient oesophageal pacing 




Aim: To design a technique for outpatient assessment of LAPWI using oesophageal pacing. 
Methods: A preliminary study confirmed the feasibility of oesophageal pacing in an outpatient 
setting using fluoroscopy on a healthy volunteer. Further patients were recruited who were 
undergoing left atrial posterior wall isolation via catheter or hybrid ablation. Patients who had 
undergone the lesion set were bought in for standalone study, fasted. An electrode was passed 
nasally or via mouth to the oesophagus under fluoroscopy and electrograms analysed using a pacing 
system analyser. Atrial pacing was then attempted. Entrance and exit block from the oesophagus 
was recorded. If no atrial electrograms were seen and we were unable to pace from the oesophagus 
LAPWI was assumed. 
Results: Eight patients (6M, 2F) were studied without complication. 5 patients had undergone hybrid 
AF ablation, 3 catheter ablation. The procedure was well tolerated. In 4/8 it was possible to pace the 
left atrium from the oesophagus, two of these patients had AF recurrence following ablation. 
Conclusions:  Standalone oesophageal pacing catheters can be used safely and feasibly to follow-up 








Oesophageal pacing can be used to check for left atrial posterior wall isolation (LAPWI) and has 
excellent positive and negative predictive value when compared to concurrent intra-cardiac study as 
seen in chapter 5. The aim of this study was to design a technique for outpatient assessment of 
LAPWI using oesophageal pacing.  
6.3 Methods 
 
Participants were recruited from patients referred to the electrophysiological service at Derriford 
Hospital, Plymouth. Full ethical approval was granted by the Devon and Cornwall research Ethics 
Committee prior to recruitment and all patients gave written informed consent.   
 
All participants in this study were undergoing ablation for persistent atrial fibrillation involving left 
atrial posterior wall isolation. This was either via a standalone catheter ablation using the ‘box’ 
lesion set or the two-stage hybrid ablation described in chapters 2 and 3.  Patients selected for 
outpatient standalone study were selected from patients who had undergone hybrid ablation who 
had been found at the second stage catheter ablation procedure (greater than 2 months from the 
surgical ablation procedure) to have complete posterior wall isolation and in whom further left atrial 
catheter ablation was not necessary. 
 
At the catheter study all patients underwent radio-frequency ablation using the Velocity system (St 
Jude Medical St. Paul, Minnesota, USA) to isolate the posterior left atrial wall or to check and 
complete left atrial posterior wall isolation as part of the hybrid program. Left atrial posterior wall 
isolation, when achieved, is confirmed by entrance and exit block into and out of the left atrial 
posterior wall. 
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We aimed to develop a technique to assess LAPWI that could be performed while a patient was 
conscious and be performed in an outpatient clinic. The study was designed for feasibility and built 
on the study in chapter 4 of oesophageal pacing during electrophysiological study. Results reported 
included the tolerability and complication rate of this technique. We also compared the findings with 
the result of the previous ablation where the left atrial posterior wall had been isolated. We did not 
seek ethical approval to re-study patients undergoing standalone oesophageal study with further 
invasive electrophysiological study although this may be performed as part of standard clinical care. 
6.3.1 Standalone Oesophageal study  
 
6.3.1.1 Preliminary study 
 
Prior to the ethical submission the tolerability of the procedure was tested by myself with the 
lubricated oesophageal electrode passed nasally (figure 6-1). I was then able to atrially pace myself 
using a temporary pacing box and check an atrial-pacing threshold which was shown to be 10 mA. 
The procedure was tolerable, with a warm feeling notable in the centre of the chest during pacing, 
although the lidocaine lubrication gel used (Instillagel) was uncomfortable. Subsequent studies 
utilized standard lubrication gels with the option of xylocaine pharageal spray if significant 
discomfort was noted. 
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Figure 6-1 Demonstrating the use of an oesophageal pacing catheter myself and testing a 
pacing threshold in an outpatient setting. 
 
 
6.3.1.2 Outpatient Studies 
 
All cases were performed with the patient fasted, conscious and without sedation. The oesophageal 
catheter was passed nasally in all cases with the patient sat up on the bed. Once in position at 40cm 
depth from the nares the patient lay down on the bed and the catheter was screened with 
fluoroscopy and adjustments made to place the middle two poles behind the left atrium (Figure 6-2). 
Three patients who had difficulty swallowing the catheter were able to swallow the catheter once 
oropharyngeal xylocaine spray was used.  
 
Atrial sensing was achieved by connecting the oesophageal catheter to a pacemaker-system-
analyser (PSA) (Medtronic, Minneapolis, USA). A temporary pacing box was used to attempt to pace 
the heart. Left atrial posterior wall isolation entrance block was assumed to be present if atrial 
signals were not seen on the PSA when the catheter was in position behind the left atrium. Left atrial 
posterior wall exit block was assumed to be present if we were unable to capture the left atrium at 
20mA@10ms from the middle two poles of the oesophageal electrode (as had been seen in 
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simultaneous study). Capture of the atrium was determined by acceleration of the atrial rate with 
pacing as seen on the continuous surface ECG. 
 




Eight patients were studied as a standalone procedure, two of whom had previously been studied 
during an ablation procedure. 
6.4.1 Oesophageal study as a standalone procedure 
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The standalone procedure was well tolerated and all patients in the study were able to tolerate the 
procedure comfortably. Two out of the eight patients required an anaesthetic xylocaine pharyngeal 
spray but the other patients tolerated the passing of the catheter with lubrication only. No patients 
required sedation for the procedure. 
 
Of the eight patients who underwent the standalone procedure five had undergone successful left 
atrial posterior wall isolation via surgical ablation and had not required further ablation at the 
second stage electrophysiological study. Two patients had undergone left atrial posterior wall 
isolation but had AF recurrence and one patient had undergone two catheter ablations to achieve 
left atrial posterior wall isolation and was due surgical closure of an atrial septal defect. 
 
Six of these patients had undergone electrophysiological study previously and the left atrial posterior 
wall had been shown to be isolated at a study remote from the time of isolation. In five of these, the 
left atrium was shown to be electrically silent with no sensing from the oesophagus and we were 
unable to pace the atrium from the oesophagus in the same five. In the two patients who had 
undergone catheter ablation with the box lesion set but had subsequently developed breakthrough 
atrial fibrillation we were able to pace the atrium from the oesophagus. One patient had undergone 
surgical AF ablation only with left atrial posterior wall isolation but remained in sinus rhythm and we 
were able to sense and pace the atrium. Repeat invasive study of these 3 patients had not yet been 
performed at the time of this study.  
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Table 6-1 Summary of standalone oesophageal study patients 
 
Key - LA – Left Atrium, OP – oesophageal pacing, PW – left atrial posterior wall, EPS block – invasive entrance and exit block, OP PW block 
– oesophageal entrance and exit block. 
6.4.2 Complications 
 
No complications were seen. 
6.5 Discussion 
 
Oesophageal pacing catheters are rarely used outside of paediatric populations for emergency 
purposes273. Likewise the historic use of oesophageal catheters for study and diagnosis of supra-
ventricular tachycardias in adults274 has been superseded by invasive electrophysiology. More 
recently oesophageal electrophysiological study has been used for ambulatory monitoring and 
investigation for atrial fibrillation275. The main advantage of the technique is the superior 
visualisation of atrial activity and P waves when compared to surface ECG’s276.  
 
This study was designed to develop a technique of checking left atrial posterior wall isolation from 
the oesophagus using oesophageal pacing catheters in an outpatient setting. The technique allows 
for follow-up of patients who have undergone left atrial posterior wall isolation via surgery or 
catheter ablation. This could be utilized for research purposes or to identify those patient’s with 
reconnections into the posterior wall following ablation and may therefore be prone to late 
recurrence of atrial fibrillation. In future larger studies it will be important to report on findings at 




(mm) Study	Arm AF	Ablation Depth(cm)
Pace	with	atrial	
capture Threshold Complications Comments
1 M 1.74 47 Standalone Hybrid 40 yes 10mA@10ms nil No	invasive	EPS	as	DOAC	not	stopped	
2 M 1.81 46 Standalone Hybrid 47.5 no no	capture@20mV nil 	
3 M 1.86 58 Standalone Hybrid 41 no no	capture@20mV nil 	
4 M 1.7 46 Standalone Hybrid 40 no no	capture@20mV nil
5 F 1.6 40 Standalone Catheter 38 no no	capture@20mV nil 	
6 M 1.72 39 Standalone Hybrid 45 yes 10mA@10ms nil 	
7 M 1.85 34 Standalone Catheter 43 yes 10mA@10ms nil Previous	EPS	study	with	AF	recurrence
8 F 1.7 38 Standalone Catheter 40 yes 12	mA@10ms nil Previous	EPS	study	with	AF	recurrence
Demographic	data Procedure	details Oesophageal	pacing	(OP)	details
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oesophagus. Previous studies have suggested that incomplete LAPWI is associated with late 
recurrence of AF226 and Chapter 2 of this thesis also demonstrated better outcomes with complete 
LAPWI. More evidence is necessary before further electrophysiological study and ablation could be 
recommended for asymptomatic patients with positive oesophageal pacing who remain in sinus 
rhythm. Currently any decision on further invasive study needs a symptomatic justification in 
addition to the oesophageal pacing findings 
 
The studies performed were uncomplicated and well tolerated. We had initially believed that we 
would be able to predict the level of the left atrium by using patient height and that visualisation of 
the catheter via fluoroscopy might not be needed. A technique for this has been described279 but we 
found it did not accurately predict the depth required for oesophageal pacing as seen in table 6-2 
below which includes all cases in chapter 5 and 6.  
Table 6-2 Predicted depth of oesophageal pacing by height (all values cm) 
Patient Height  Predicted depth Actual depth Diff 
166 34.5 40 5.5 
185 39.25 43 3.75 
180 38 42.5 4.5 
182 38.5 45 6.5 
174 36.5 40 3.5 
169 35.25 34 -1.25 
177 37.25 42.5 5.25 
181 38.25 47.5 9.25 
186 39.5 41 1.5 
170 35.5 40 4.5 
160 33 36 3 
180 38 45 7 
180 38 40 2 
186 39.5 50 10.5 
178 37.5 45 7.5 
180 38 46 8 
183 38.75 42 3.25 
170 35.5 40 4.5 
176 37 40 3 
165 34.25 40 5.75 
160 33 38 5 
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172 36 45 9 
 
 While correlation exists between the patient’s height and the depth required to pass the 
oesophageal catheter, a few seconds of fluoroscopy adds a greater accuracy to the procedure at 
minimal additional risk to the patient.  It may be that further study increases the accuracy of using 
the oesophageal catheters “blind” but we would currently recommend fluoroscopy in all cases.  
6.5.1 Limitations of the Study 
 
This is a small feasibility study of a novel technique. A larger study is ongoing and may reveal more 
limitations. Our aim in the standalone technique was to develop a technique that could lead to 
further study and this is clearly required to calculate positive and negative predictive values. It will 
also be important to compare the standalone study with subsequent invasive EPS. 
6.6 Conclusions 
 
Standalone oesophageal pacing catheters can be used safely and feasibly to follow-up patients who 
have undergone left atrial posterior wall isolation in the treatment of atrial fibrillation. Larger studies 
are necessary to define a role for this technique and the AF recurrence rate in patients who it is 
possible to pace the left atrium from the oesophagus.  
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7 Chapter 7 - The development of new catheter technologies in the 
ablation of Atrial Fibrillation: Electrical isolation by electroporation 
of right ventricular myocardium in an ex-vivo beating porcine 




Background: Electroporation is a mechanism where the cellular response to large electrical pulses 
triggers apoptosis. Novel ablation catheters have utilised this technique for ablation in animal 
models. We sought to establish whether the Alert internal cardioversion catheter could deliver linear 
ablation lesions via electroporation. The aim of this study was to demonstrate electrical tissue 
isolation using high-energy biphasic defibrillation shocks delivered in linear lesions via the Alert 
catheter in beating ex-vivo porcine hearts.  
Methods: Two recently recovered porcine hearts were placed in a specialised water bath, perfused 
and oxygenated ex-vivo to continue beating while the experiments were conducted. The right 
ventricular free wall was chosen as the site for electroporation due to size, thickness and 
accessibility. For each heart a temporary pacing box and pacing wires were used to stimulate the 
heart and pace to 90bpm from the centre of the RV free wall. A suture was placed at the point of 
pacing to mark the site, the pacing wires removed, and linear lesions delivered to the RV free wall 
around the suture using the Alert catheter connected to a biphasic defibrillator (Phillips Heartstart 
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XL). Pacing was then attempted at the site of the suture within the ablation "box" lesion set and 
outside the electroporation lines. Electroporation was attempted with energies of 200J 100J and 50J.  
Results: Using energies of 100J biphasic defibrillation and linear lesions it was possible to isolate a 
discreet triangular area of the right ventricular free wall on the two experimental hearts with exit 
block confirmed by pacing inside the isolated areas without conduction out to the surrounding 
myocardium. Pacing outside the isolated area continued to capture the rest of the myocardium.  
Defibrillation at 200J caused steam pops, arcing and discolouration of the myocardium. Following 
this it was not possible to pace the myocardium even at 20mA10ms one centimetre either side of 
the ablation line. 50J energy appears insufficient, as it was possible to pace the myocardium 
following energy delivery. 100J however did not result in steam pops or arcing and it was not 
possible to capture myocardium when pacing along the electroporation lines.  
Conclusions: Electrical isolation of right ventricular myocardium was possible using 100J biphasic 
defibrillation delivered through an Alert catheter. Further research is needed to investigate lesion 










Electroporation is a mechanism where the cellular response to large electrical pulses changes the 
permeability of cell membranes and under the correct conditions triggers apoptosis280.  Recent years 
have seen a number of clinical uses such as using electroporation to allow the opening of cell 
membrane pores for delivery of genetic material to targeted ablation for malignant tumours280–282. A 
specific advantage of using electroporation for targeting malignant tissue is the minimising of 
damage to surrounding structures and tissues283.  
 
Recent study has shown electroporation to be feasible in animal models for the purpose of cardiac 
ablation284–289. The speed of the technique and apparent safety with regard to surrounding tissues 
and structures such as coronary arteries has made this an attractive focus for future catheter 
ablation development286.  No trials in humans have been performed as yet although the technique 
has similarities to fulguration, an early ablation technique that used higher energies and was 
consequentially hampered by phenomena such as arcing and barotrauma that led to occasional 
catastrophic consequences such as cardiac rupture290–295. Fulguration used far higher energies than 
electroporation and was superseded as an ablation technique by radio-frequency ablation. 
Contemporary electroporation studies utilize novel ablation catheters and lower energies for 
ablation in animal models without causing barotrauma to surrounding structures.  
7.3 Aims 
 
We investigated whether a modified Alert internal cardioversion catheter (Model No AL-SP75149 
Dot Medical Ltd, UK) could be used for electroporation. We hypothesised that electrical isolation of 
an area of ex-vivo porcine myocardium would be possible using an Alert catheter and sought to 
establish whether a modified Alert catheter connected to a standard high-energy defibrillator would 
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allow delivery of higher energies through the catheter and following on from this whether the Alert 
catheter could deliver linear ablation lesions.  
7.4 Methods 
 
The Alert catheter is used in conjunction with the Alert Companion system for internal cardioversion 
and will deliver a maximal energy of 30J. The catheter is designed for internal cardioversion and has 
a series of six 5mm platinum-iridium bands that make up the distal shock array. Catheters in use for 
clinical internal cardioversion also include a proximal array with a distal latex balloon however the 
catheter was modified for this study with the balloon removed. The proximal array and pace/sense 
electrodes were covered with plastic insulation tape.   
 
Figure 7-1 The Alert catheter. Designed and used for internal cardioversion. For our study 
the catheter was modified by removing the balloon and covering the right atrial proximal 
shock array with electrical insulation tape 
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Our initial experiments focused on designing a setup that would allow the Alert catheter to deliver 
biphasic shocks in a water bath. A Phillips HeartStart XL biphasic defibrillator was connected to an 
ECG simulator to allow for a synchronised DC shock. This shock cable was connected to two cables, 
one of which was connected to a disposable back plate and the other to the Alert catheter. The 
backpad was placed behind a dummy heart in a shallow water bath. The dummy heart was kept 
damp and it was confirmed that biphasic defibrillation could be delivered through the distal array of 
the Alert catheter.  
 
Next we developed a system to deliver shocks ex-vivo on recovered beating porcine hearts. This was 
done on two separate days with the first day devoted to harvesting a porcine heart and setting it up 
in our lab to plan the experiments on the second day during which electroporation would be 
delivered to the porcine hearts.    
 
On the second day three beating hearts were recovered from pigs slaughtered for human 
consumption. Protocols at the slaughterhouse and laboratory were in accordance with EC 
regulations 1069/2009 regarding the use of slaughterhouse material for diagnosis and research.  The 
technique used for maintaining, oxygenating and perfusing beating ex-vivo mammalian models 
originated from Langendorff in 1895 and is well described.  
 
The beating porcine hearts were transported to the laboratory that was setup as described above 
(figure 7-2). The process took two hours and one heart was not useable after the transfer process. 
That left us with two hearts on which to conduct the experiments. 
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Figure 7-2 The setup of the lab for the experiments 
 
 
The beating hearts were maintained and perfused in the water bath solution and had an intrinsic 
rate of 60 beats per minute. We then confirmed that pacing was possible using a standard 
temporary pacing box. Wires placed on the epicardial surface of the heart with positive and negative 
electrodes spaced 5 millimetres apart. Successful capture was seen when pacing the ventricles and 
the heart rate rose to the programmed 90 beats per minute.   
 
Of the two hearts we had harvested the right ventricular free wall of the first heart was chosen as 
the site of our initial electroporation for reasons of accessibility. On the second heart we planned to 
deliver energy to the atrial endocardium and to do this would require incising the right and left 
ventricles to gain access to the atria. 
 
The Alert catheter was manually held against the right ventricular myocardium of the first heart so 
that the array and electrodes at the tip of the catheter were all in contact with the myocardium. As 
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the optimal energy in our system was unknown we planned DC shocks, synchronised to the ECG 
stimulator, delivered to the myocardium at 200, 100 and 50 joules to assess the effects and efficacy 
of each energy level.  
 
If we were able to successfully deliver electroporation via the Alert catheter then we envisaged this 
producing a linear lesion which if effective would enable us to produce a 'box' lesion pattern to 
isolate an area of myocardium.  An area of the right ventricular free wall was preserved to do this 
and marked with an epicardial suture. We aimed to demonstrate capture with bipolar pacing at this 
site initially and measure a pacing threshold before delivering linear lesions to create a box around 
this central suture. If the linear ablation was successful then we would expect to isolate the 
myocardium at the site of the suture and pacing at the site of previous capture would fail to pace the 
heart demonstrating exit block from the isolated area of myocardium. 
 
The second heart was used to repeat the process of electrically isolating myocardium through linear 
ablation in the same manner as the first heart but instead of using epicardial right ventricular 
myocardium we aimed to use endocardial atrial myocardium. To facilitate this it was envisaged that 
the ventricles would need dissecting to access the atrial endocardium. During our initial planning it 
became apparent that a porcine heart has smaller atria than a human heart and this could made 
demonstrating electrical isolation in the atrium impossible without formal electroanatomical 
mapping equipment.  
7.5 Results 
 
7.5.1  The first heart 
 
The two Pacing electrodes were manually held against the RV tissue at various sites on the epicardial 
surface and the heart was seen to be paced at 90 bpm, the rate of the external pacemaker. The 
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intrinsic rate of the heart was measured at 60 bpm. The pacer current was set at 10mA in demand 
mode. A suture was placed in the middle of the RV free wall to mark the centre of the intended area 
of isolation. 
 




7.5.2 Energy delivery of 200J 
 
The Alert catheter was place on the epicardial surface of the RV along an imaginary line to the right 
of the septal wall and after a 10J test shock, a 200J shock was delivered. A loud bang was heard, 
steam bubbles were seen, and arcing occurred at the point of shock delivery along the line of the 
catheter array and the heart was stunned. It recovered over a few moments and started to beat 
slowly again.  
 
The two manual pacing pins were placed on the heart, ostensibly to speed the heart up. It was then 
noticed that placing the pins along the intended line of lesion prevented capture but placing the pins 
anywhere else on the heart caused pacing at 90ppm. A line of electrically inert tissue that could not 
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be paced had been created by the delivery of one 200J shock. This line of isolation went through the 
heart to the endocardial surface as evidenced by pushing the pacing pins through the myocardium 
and finding it made no difference to the lack of capture.  
7.5.3 Energy delivery at 100J 
 
Given the arcing and barotrauma of the highest energy delivery it was felt that 200J was too much 
energy and it was decided to reduce the next shocks to 100J in order to prevent arcing and popping. 
 
A second and third linear lesion were made on the surface of the RV using 100J shocks to create a 
triangular shaped area of isolation which was verified using the manual pacing pins. Outside the 
isolated area, the tissue was paced at 90ppm and inside the area there was no capture at all. The 
pacing pins were pushed slowly all the way through the epicardial surface towards the endocardial 
surface but at no point did the isolated tissue capture the paced pulses.  
7.5.4 The second heart 
 
The second heart was still in ventricular fibrillation but the atria were beating regularly at 60bpm. It 
was decided to create a right ventricular flap in the hope that the ventricular fibrillation may stop. A 
vertical incision was made to the right of the right ventricular septal wall running from the base 
towards the Apex and then round and up to create a flap. Unfortunately, the ventricle remained in 
VF. 
7.5.5 Energy delivery to the Atrium 
 
It was decided to open the left atrium and display the Mitral valve from above with the walls of the 
left atrium exposed. After this surgical opening, the left atrium was still beating even though the 
walls had been opened and flattened. It was possible to pace the LA from both an anterior flap and a 
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posterior flap. It was hoped that we would be able to electrically isolate the posterior left atrium via 
electroporation. 
The Alert catheter was placed over a section of the posterior flap and a 100J shock was delivered 
with the aim of isolating the posterior flap from the rest of the left atrium. Subsequent to shock 
delivery it was impossible to pace the posterior flap but also not easy to pace the rest of the left 
atrium. It wasn’t clear due to the size of the atrium whether a linear lesion had occurred as pacing 
would only occur intermittently in the anterior portion of the LA.  
7.5.6 50J Energy delivery 
 
It became apparent that the shock or surgical procedure had reverted the RV back to sinus rhythm 
so attention was switched back to the RV flap which could now be paced at 90ppm at various sites. 
The Alert catheter was placed on the epicardial surface in a curve with the intention of isolating a 
section along the anterior left edge of the flap. A 50J shock was delivered which did not isolate this 
segment. A second 50J shock was delivered which also did not isolate.  
 
A third shock of100J was then delivered in the same position and the segment became completely 
isolated. There was no capture in the epicardial, endocardial, or wall section of the intended area for 
isolation. However, pacing capture was evident at various other sites in the RV. The pacing pins were 
slowly pushed through the myocardium of the isolated site whilst pacing to demonstrate that 
isolation was through the full thickness measured at 7mm with a micrometer.  
7.6 Discussion 
 
Electroporation is emerging as a promising technique for cardiac ablation288,296. It offers a holy grail 
for ablating electrophysiologists with the potential for rapid energy delivery to create discrete lines 
of ablation with minimal trauma to surrounding structures297.  A range of uses in clinical medicine 
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already exists such as the delivery of genetic tissue and the destruction of solid tumours as a cancer 
treatment. Research in these areas has led to the potential for use in cardiology and we now have a 
greater understanding of the effects of controlled bursts of energy to cell membranes. The proposed 
mechanism for electroporation is the that certain energy levels cause permanent opening of cellular 
channels, influx of calcium into cells and the triggering of apoptosis. This leads to discreet areas of 
cell death and fibrosis280,298.  
 
A number of animal studies now exist to show that ablation is possible and safe in the limited 
number of cases published so far286–288. This is in comparison to the historic predecessor of 
electroporation, the technique of fulguration. Fulguration was superseded by radio-frequency 
ablation but was at one time used widely as an ablation technology where high energy was delivered 
directly to the heart. It’s major limitation was safety as delivering high levels of energy directly to the 
heart resulted in steam pops, barotrauma , significant morbidity and mortality291,299. So far the 
animal studies of electroporation have not shown this.  
 
Our study demonstrates that linear ablation lines can be created by delivery of direct current to 
epicardial myocardium through a modified ALERT catheter. It would appear from our study that 100 
joules was the best energy level of the three that we tested, providing enough energy to create 
lesions while not producing the steam pops that could cause barotrauma. This may be further 
refined by more study both ex-vivo and in animal models.  
 
Our assumption is that the ablation lines are created via electroporation but to further test this 
hypothesis it would be necessary to keep the hearts beating longer and perform histological studies. 
This was not planned as part of this study and using Langendorf hearts would limit the amount of 
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histological study possible. The process of electroporation is known to continue after energy has 
been delivered due to the induction of cellular apoptosis through the opening of cell membrane 
pores. This may mean that by keeping the hearts beating for longer, rather than recovery of 
myocardium and the formation of gaps, it may be that ablation lines solidify. This raises the prospect 
of lower energies causing a delayed apoptosis and being potentially usable and ultimately safer.  
 
 It will be important that these experiments are reproduced in animal models where the animals can 
be recovered and studied at a later date to look for histological changes and assess the degree of 
recovery or extension of the linear ablation lines. A study similar to those published porcine studies 
would allow assessment of the width, depth and durability of each lesion plus give safety 
information. 
 
This study demonstrates that with modification the Alert catheter can deliver higher energies than 
intended thus making electroporation feasible. In this study it was held manually against the 
epicardium for the purpose of energy delivery but for the catheter to be used for endocardial 
ablation it will need a means of control and stability to allow adequate contact. This is likely to be 
through modification of the catheter itself so that it is steerable but could involve a conventional 
steerable catheter as a buddy to hold the array in place or an alternative means of fixation to deliver 
electroporation. Further research and development will be necessary before studies on live animal 
models are possible.  
 
7.6.1 Limitations of study 
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This was a small study on two ex-vivo hearts and was designed to test the feasibility of our 
hypothesis. Due to the small numbers, the limited time we were able to keep the heart beating and 
the lack of any histology caution is needed about the mechanism durability of electrical isolation.  
7.7 Conclusions 
 
Electrical isolation of myocardial tissue can be achieved by delivering single biphasic defibrillator 
shocks of 100J through the linear array of an Alert catheter. 100J shocks were sufficient to isolate an 
area in 7mm thick tissue where as 50J was insufficient to isolate 7mm tissue. At higher outputs of 
200J steam pops and arcing were seen but a lower output of 50J was insufficient to isolate an area of 
myocardium. Further study is required to investigate the size, depth and durability of the lesions 
with histological analysis important in any future studies. Further research will also be necessary to 
optimise catheter design and energy delivery. 
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8 Chapter 8 – Conclusions 
 
Atrial fibrillation has been studied for over 100 years and advances in catheter ablation over the past 
20 have led to an explosion in available treatments. Despite this, there is much that is yet to be 
understood. In the introductory chapter I described the competing theories of AF pathophysiology 
that have ebbed and flowed with time as the science has evolved. It remains unclear what the 
specific roles of triggers and substrate are that allow the initiation and propagation of the most 
common arrhythmia seen in human beings. Consequentially it is perhaps inevitable that what to 
target in AF ablation is uncertain.  
 
Paroxysmal AF in the great majority of patients originates from triggers in the pulmonary veins and 
therefore the rationale for pulmonary vein isolation is easily understood. Persistent AF is more 
complex and with a heterogeneous group of patients it is unsurprising that a variety of ablation 
targets and lesion sets, as summarised in chapter 1, are used. None of these have been shown to be 
superior to pulmonary vein isolation alone but more complex patients with longer continuous AF 
durations, left ventricular dysfunction and larger left atria are unlikely to achieve good long-term 
outcomes with the simplest AF ablation lesion set.  
  
When I originally started the planning for this thesis the intention was to design and run a head to 
head trial of hybrid AF ablation versus catheter ablation in patients with persistent AF looking at 
freedom from atrial arrhythmia. This was based around the existing Hybrid AF program in Plymouth. 
It became clear prior on starting my research that a trial of this size was not going to be feasible in 
the time available. Instead it was decided to conduct a series of smaller studies to inform a future 
larger head to head study. The data was intended to be mainly prospectively collected but, as it 
collected from day-to-day clinical practice at a busy NHS hospital that regularly experienced bed 
Left Atrial Posterior Wall isolation for the treatment of Persistent AF Guy Furniss 
 152 
crises resulting in regular procedural cancellations, this was not possible. Consequentially I used 
retrospective data for a number of cases in the catheter ablation study. While this only represented 
24% of cases (8/33) data had to be collected from notes and I was unable to acquire the information 
as accurately as I could prospectively. 
 
The technique of oesophageal pacing was not originally a major part of the plan for the thesis but 
was an idea expanded on early in my research time. After showing it was possible to pace the atrium 
during an AF ablation procedure, I designed and conducted a study to look at feasibility of the 
technique and how it could be incorporated into the management of patients undergoing left atrial 
posterior wall isolation. Oesophageal pacing grew to form a large part of my thesis and is continuing 
to be studied. A thesis looking at its application alone should be considered by a future researcher. 
 
8.1 Left Atrial Posterior Wall Isolation 
 
In this thesis left atrial posterior wall isolation for the treatment of persistent atrial fibrillation is 
studied. Chapters 2 and 3 are observational studies looking at current practice at Derriford Hospital 
Plymouth with left atrial posterior wall isolation via catheter and hybrid ablation respectively. Both 
techniques result in the same lesion pattern following the catheter ablation alone or the 2nd catheter 
ablation stage for hybrid ablation.  
 
For a clinical trial comparing the two techniques to be designed it is important to assess the 
respective outcomes and complication rates for the procedures. Both series demonstrate promising 
rates of freedom from atrial arrhythmia, which appear marginally higher than the STAR AF II lesion 
sets138 at one year, especially if the lesion set is intact. However, these are non-randomised series of 
patients in whom the baseline characteristics differ, so caution is required without further studies. 
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As the practice at Derriford is to offer hybrid ablation to longstanding AF patients with larger left 
atria one would expect worse outcomes in the hybrid group. For the catheter ablation group in 
chapter 2 the median left atrial diameter was 40mm (IQR 35-45) with a continuous AF duration of 8 
months (IQR 2-12). In chapter 3 for the hybrid group the median left atrial diameter was significantly 
larger at 46mm (43-49) with a longer continuous AF duration of 24 months (13.75-35.75). Due to the 
large discrepancy between the groups I chose not to do formal statistical comparison for the 
ablation outcomes, as these would not have been valid. 
 
These results are further confounded by the impact of two procedures in the hybrid group where an 
advantage over the single procedure in the catheter cohort should have had specific outcome 
benefits as gaps in the lesion set from the first procedure can be identified and treated.  
 
As shown in chapter 1 previous small studies of left atrial posterior wall isolation have shown 
promise compared to pulmonary vein isolation alone. This thesis suggests that it is a encouraging 
technique but it is important that the lesion pattern is compared to pulmonary vein isolation in 
larger randomised studies.  
 
8.2 The importance of an intact lesion set and how to maximise ablation success to 
improve outcomes 
 
The importance of a complete lesion set with confirmed entrance and exit block from the LAPW was 
demonstrated in chapter 2. Where this was confirmed, 74% remained arrhythmia free at a median 
of two years follow-up. If repeated consistently this finding would point to a superiority of the lesion 
pattern over pulmonary vein isolation, albeit in a mixed non-randomised group. As discussed in the 
introduction, there is variable success in complete LAPW isolation via catheter with the 70% success 
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rate in chapter two reflective of other contemporary studies.  The rates of successful LAPW isolation 
in the hybrid group were higher and an advantage of a two-staged procedure is that it allows for 
recovery of the myocardium so that gaps are identified at the second stage and the ablation lines 
can be touched up and completed. Previous work from HIFU ablation from our group showed an 
association with long term freedom from AF if the LAPW was isolated226.  
 
A two procedure strategy has been proposed routinely for pulmonary vein isolation by Das et al who 
showed re-connection of ablation lines in 26% of pulmonary veins at two months228. A two-stage 
strategy for catheter ablation for LAPWI needs consideration but the ethics of repeating 
electrophysiological study in asymptomatic patients and exposing them to procedural risks is 
questionable. The counter argument to this is that risks are low from the procedure and if outcomes 
are better with two stages then they are worth taking. This would be especially true if it was 
demonstrated that rates of LAPWI are higher after two catheter ablation procedures than one.  
 
Clearly further study is needed to answer this question but there may be a role for oesophageal 
pacing as described in chapters 5 and 6 to reassess the lesion set following a first ablation both in 
research trials and clinical practice. This simple technique could be used to identify those patients 
who are at greater risk of AF recurrence. If the posterior wall is not isolated, then this could trigger a 
further catheter ablation or identify a cohort of patients who need close observation and follow-up. 
A prospective observational study looking at LAPWI as identified via the oesophageal catheter two 
months post catheter ablation should be performed. I would hypothese, based on this thesis, that 
the group of patients in whom oesophageal pacing is possible would be at greater risk of recurrence 
of atrial fibrillation.  
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I had originally planned to make greater use of the three-dimensional maps created prior to catheter 
ablation and at the catheter ablation stage of the hybrid group. This could have allowed comparison 
of low voltage signals and atrial scar pre ablation for the catheter ablation chapter and also following 
the surgical ablation in the hybrid ablation chapter. Unfortunately, due to a failure to back up the 
procedures a large proportion of data was lost and could not be recovered in sufficient quantity to 
make the analysis worthwhile during the period of my study. This is certainly a possibility for future 
study and as the volume of cases increases with time it would be of great interest to look at burden 
of atrial scar, it’s location and whether it has an effect on outcomes. 
 
The experimental electroporation chapter is not an obvious fit within the scope of this MD thesis. 
While the thesis was in the planning stages preliminary experiments on modifying the ALERT 
catheter were conducted. These are described in the introduction of chapter 7. It was hoped that 
with further evolution of the catheter more studies would have been performed in my period of 
research. Logistically and financially, arranging Langendorf animal models for further investigation is 
necessary to build on the preliminary investigations. I had hoped that further study would have 
allowed us to electrically isolate the left atrial posterior wall via electroporation. As chapter 7 
describes, electroporation was attempted in the atrium, but the myocardium was too thin and out 
equipment to sense and pace the atrial tissue too simplistic. To do this would require three-
dimensional mapping equipment that was not available to us.   
 
While different surgical ablation technologies as described in Chapter 1 are available, improving 
outcomes of ablation at the first stage will be difficult. In Chapter 3, as experience with surgical 
ablation increased an increasing number of energy deliveries were given to achieve LAPWI. However 
this did not see an improvement in outcomes following surgical ablation over the study period. It is 
almost certain that ablation technology will improve but techniques such as electroporation in 
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chapter 7 offer a “holy grail” of a one-shot energy delivery that results in more durable lesions and 
complete ablation lines.   
 
To improve outcomes of LAPWI with the current technology described in chapter 2 and 3 I suspect 
the only option would be more ablation and more rigorous testing resulting in longer procedures. 
Yet longer procedures and more time spent trying to isolate the LAPW will increase anaesthetic time 
and complications due to increasing volume of ablation. A technique such as electroporation that is 
quick and doesn’t damage surrounding tissues reduces both these risks.  
 
8.3 Differences between catheter and hybrid ablation 
 
 
As stated above, the groups of patients in Chapters 2 and 3 were not evenly matched and therefore I 
did not feel it was possible to meaningfully compare outcomes between catheter and hybrid 
ablation. This was the original idea behind the thesis and so I looked at left atrial posterior wall 
isolation via two methods through two series and the surrogate marker of P wave duration. Direct 
comparison is problematic as the hybrid ablation patients had longer continuous AF durations, larger 
left atria and longer P wave durations at baseline. However, outcomes were similar in both groups 
despite these negative factors in the hybrid group. Also, a more marked reduction in P wave 
duration was seen in the hybrid group. I have proposed that this is either due to more enduring 
lesions in the hybrid ablation group or autonomic modulation from the direct targeting of ganglionic 
plexi, although it could reflect a more durable and intact lesion with a two-stage procedure. 
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The two-stage procedure allows for any gaps in the ablation to be identified and re-ablated, meaning 
better outcomes due to an enduring and more consistent lesion set. However, the targeting of 
autonomic triggers can improve outcomes of atrial fibrillation ablation and using botulin toxin 
injected into the GP’s following cardiac surgery reduces AF recurrence152. The location of ganglionic 
plexi on the posterior left atrium around the pulmonary veins means that they are often ablated 
with routine pulmonary vein isolation. Freedom from AF may be improved when GP ablation is 
added to PVI148 and persistence of ganglionic plexi responses has been associated with worse 
outcomes following catheter300 and surgical ablation301 for AF.  
 
During the study period for this MD I was involved in a study mapping ganglionic plexi at ablation for 
paroxysmal atrial fibrillation using a GRASS stimulator302. This uses high frequency stimulation to 
identify ganglionic plexi by inducing a vagal response with bradycardia and occasional hypotension 
when a GP is stimulated endocardially255,303. Surgical identification of ganglionic plexi works on the 
same principle with high frequency stimulation on the epicardium identifying ganglionic plexi that 
can then be excised.  This is how the GP’s are identified prior to surgical excision in the surgical stage 
of the hybrid AF ablation pathway described in chapter 3. 
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Figure 8-1 The GRASS stimulator 
 
Follow-up study of the ablation of ganglionic plexi responses in animal models have demonstrated 
that reinnervation is common304 and autonomic recovery could impact on outcomes. It has been 
proposed that epicardial ablation provides more enduring autonomic modulation that endocardial 
catheter ablation and offers a potential advantage over catheter ablation alone. I therefore designed 
a study where the ganglionic plexi are mapped before and after left atrial epicardial ablation and GP 
excision (IRAS 165064). The reduction in GP responses are recorded and re-mapped at catheter 
second stage to see whether they recur. The hypothesis is that Epicardial ablation eliminates GP 
responses and that mapping of GP pre and post-surgical epicardial ablation will demonstrate a 
reduction in GP responses that will persist to the endocardial second stage. In this study it will also 
be interesting to observe any changes in the surface ECG P wave that correlate with autonomic 
modulation to test the hypothesis in chapter 4.  
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The study has started but recruitment had not been sufficient for this work to be included in this 
thesis.  
 
8.4 Designing a head-to-head trial of catheter and surgical ablation 
 
 
A future trial comparing hybrid ablation and catheter ablation should focus on symptomatic 
persistent atrial fibrillation patients and compare a two-stage hybrid ablation with a two-stage 
catheter ablation approach.  It should compare the same lesion pattern, using the Cobra Fusion 
device in the hybrid group with a second stage catheter ablation to complete left atrial posterior wall 
isolation. The catheter ablation to isolate the left atrial posterior wall should be as described in 
chapter 2. Using the series in chapters 2 and 3 as a basis for a future trial due to the limitations 
explained previously regarding different patient populations with a predominantly long-standing 
persistent AF population undergoing hybrid ablation with the catheter ablation population having an 
overall shorter AF duration. 
 
Given the outcomes of the two procedures for persistent AF in our series was 58% freedom from 
arrhythmia recurrence for catheter ablation at 24 months and 60% in the hybrid group a power 
calculation can be performed. For 90% power at an alpha value of 0.05 and with 1:1 randomisation 
262 patients would be needed. This is a large number to recruit and therefore a non-inferiority study 
could be appropriate given the expected increased complication rate seen with surgical and hybrid 
AF ablation.  
 
A study comparing surgical AF ablation using bipolar bilateral ablation clamps and a RF pen with 
catheter ablation for longstanding persistent atrial fibrillation is currently on-going222.  This is the 
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first trial of its kind in that it is comparing equivalent lesion patterns, although the catheter group 
will also receive mitral and tricuspid isthmus lines. Implantable loop recorders will be used as 
standard so accurate assessment of AF burden will be possible in both groups with symptom scores, 
complication rates and health economic analysis also reported.  As discussed in the introduction, 
series of surgical and hybrid ablation do appear to show better freedom from atrial fibrillation but 
this comes at a cost in terms of complications. Comparative studies are therefore essential to allow 
clinicians and patients to assess the risks and benefits of the two approaches.  
 
8.5 Future uses for oesophageal pacing 
 
 
The oesophageal pacing technique described in chapter 5 is a potentially valuable tool. Identifying 
those patients with an intact LAPW lesion pattern and entrance and exit block following a prior 
ablation could allow earlier discontinuation of anti-arrhythmic drugs and greater confidence of long-
term success with rhythm control. For those that do not have demonstrable block via the 
oesophagus a further ablation or closer follow-up could be recommended.  
 
The technique could be incorporated into trials of hybrid and surgical ablation as a non-invasive 
marker of posterior wall isolation following the epicardial ablation. In a trial of hybrid versus 
catheter ablation this could be integrated into the protocol to test for left atrial posterior wall 
isolation following each stage of the study. If a two-stage procedure is planned then mapping of the 
left atrium and completion of the ‘box’ lesion pattern would not be mandated in patients who 
remained in sinus rhythm at one month follow-up and in whom it was not possible to capture the 
left atrium from the oesophagus.  
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Prior to the inclusion of this in any research protocol of a randomised trial comparing catheter and 
hybrid ablation more studies are required to validate this technique. An outpatient series in patients 
who have had recurrence of AF after LAPWI is currently on-going at Derriford hospital, Plymouth. 
The oesophageal study is performed in a pacing lab using fluoroscopy to guide the catheter and 
sensing and pacing are assessed. If the patient is in persistent atrial fibrillation the procedure is 
performed following a DC cardioversion. All patients with recurrence of arrhythmia are listed for 
repeat catheter ablation as standard and we will be able to compare the findings of the oesophageal 
study with the subsequent catheter study.  
 
It would be interesting to set up a study of surgical AF ablation patients who have undergone LAPWI 
via a MAZE or thorascopic procedure where an oesophageal study is used at three months to check 
the lesion set. The hypothesis would be that in those patients where it is possible to capture the left 
atrium a higher rate of AF recurrence would be seen. Previous work at our centre by Davies et al 
showed an association between long-term freedom from AF recurrence and ongoing LAPWI in 
patients who had previously undergone high-frequency focussed ultrasound for AF during 
concomitant surgery226. The importance of successful left atrial posterior wall isolation in freedom 
from atrial fibrillation was also seen in the catheter ablation series in chapter 2. Patients with the 
complete lesion set had better outcomes than those in whom LAPWI was not possible. These 
patients could be offered a second catheter ablation to complete the lesion set as standard rather 
than wait for recurrence. In those in whom successful LAPWI was achieved further intervention 
could be determined by on-going oesophageal study.  Alternatively, asymptomatic patients in whom 
it is possible to pace from the oesophagus could be more closely followed up. One could hypothesise 
that there may be more sub-clinical AF in this group of patients that could be detected on 
ambulatory monitors or implantable loop recorders.  
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In the first instance it is key to validate the technique with further studies. For oesophageal pacing to 
be used in a more widespread capacity, proving the benefits of LAPWI in the management of 
persistent AF will be necessary. Decisions to repeat electrophysiological study and ablation in 
patients based solely on oesophageal pacing results are not currently justifiable in the absence of 
symptoms. This thesis would suggest that an intact lesion set and durability of LAPWI is key to 
outcomes. Consequentially if it can be proven in wider studies that the oesophageal pacing 
technique can identify patients without an intact lesion set one would expect an increase in 
arrhythmia recurrence in these patients.  
 
In those patients in whom it is not possible to pace the left atrium from the oesophagus but who 
have had recurrence of AF the hypothesis of this thesis would point to AF triggers outside the left 
atrial posterior wall. While this may be a macro-re-entrant atrial flutter, which would be amenable 
to further ablation, it could point to widespread atrial fibrosis and substrate that would be harder to 
treat with ablation. In this circumstance the oesophageal study in conjunction with what is known 
from the previous catheter ablation might point to poorer outcomes from repeat study and 
acceptance of a rate control strategy. If all the data was available from the mapping procedures in 
the series in this thesis scar burden inside and outside of the LAPW could be analysed against AF 
recurrence.  
 
8.6 Future directions for catheter ablation 
 
Outcomes from ablation of persistent atrial fibrillation remain significantly worse than for 
paroxysmal atrial fibrillation where the well-established lesion set of pulmonary vein isolation is an 
effective treatment in over 80% of patients. PVI alone has also been shown to provide one year 
freedom from AF of 59%138 . It is therefore a reasonable first approach, adopted by many centres, for 
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patients with persistent AF provided we accept that a significant number will have recurrence. 
Currently there is little evidence to justify alternative lesion patterns over PVI but isolating the left 
atrial posterior wall needs to be considered as either an alternative initial approach or a second line 
procedure. Improvements in ablation technology that allow for more durable ablation lesions 
without increase in procedural risks may mean that LAPW isolation via catheter, surgical or hybrid 
ablation is a first line option for persistent AF in future. At present the more complex procedures are 
mostly reserved for those with long-standing persistent AF.  
 
New catheter technologies incorporating electroporation potentially offer a quicker procedure with 
lower risks. The results of Wittkampf’s initial animal studies with electroporation is highly promising 
and suggest a potential role in both epicardial and endocardial ablation284–288,305. If it can be shown 
that electroporation can give rise to durable ablation lesions, then human study is not far away with 
alternative catheter technologies utilizing electroporation to ablation either epicardially or 
endocardially. The modified ALERT catheter allowed for linear ablation. Given that, isolation of the 
left atrial posterior wall could theoretically be performed with four ablation lines. If technology such 
as this could reliably isolate the posterior wall of the left atrium with minimal risks to adjacent tissue 
it could be a valuable tool for the electrophysiologist. Even if the linear ablation was just used for 
roof or floor lines this is advantageous as it would reduce the risk of damage to the oesophagus, 





Persistent atrial fibrillation is difficult to treat and its complex pathophysiology, mechanism of onset 
and propagation are not fully understood. Catheter ablation is better for long-term maintenance of 
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sinus rhythm than anti-arrhythmic drugs but ablation outside of isolating the pulmonary veins has 
not been shown to improve outcomes.  Much future study is required to answer questions about the 
best approach for ablation of persistent and long-standing persistent AF. This thesis demonstrates 
the promise of LAPW isolation and some of its potential advantages over other lesion sets. 
Randomised comparison is crucial however, both between ways of delivering the lesion pattern and 
against other patterns such as PVI.  
 
Studies comparing catheter ablation with hybrid and surgical ablation are limited. From series that 
have been performed previously, and from this thesis, it appears that surgical ablation may have 
benefits in terms of reduction of arrhythmia but carry a cost in terms of complications. Many of 
which are major complications. This may ultimately limit surgical techniques and see catheter 
ablation as the long-term treatment of choice. This is especially true while AF ablation remains a 
treatment for symptoms without proven prognostic benefits in the majority of patients.  
 
 In future studies the technique of oesophageal pacing can be used for follow-up and monitoring of 
patients. The aim would be to guide the need for repeat procedures which could be offered to those 
who would potentially gain most. This could both help identify those most at risk of arrhythmia 
recurrence and reduce the need for unnecessary procedures in those who have intact LAPW lesion 
sets. 
 
The issues around outcomes from ablation with regard to freedom from arrhythmia and risk of 
procedural complications may point to the limitations of conventional ablation techniques. 
Technological improvements such as electroporation are therefore vital in the advancement of this 
field. While chapter 7 isn’t an obvious fit into this thesis I feel that what I have highlighted in the 
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introduction is the limitations of ablation in persistent AF and while LAPWI may offer some 
improvement there is a long way to go. Electroporation is very attractive and human studies will not 
be too far off. The promise of a safer and better ablation technique in addition to a superior lesion 
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